var title_f43_28_44480="Forearm fx";
var content_f43_28_44480=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Forearm fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 515px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    10-year-old with complete fracture of ulna with 30 degrees angulation. Note accompanying buckle fracture of distal radius.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paula Schweich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_28_44480=[""].join("\n");
var outline_f43_28_44480=null;
var title_f43_28_44481="Risser sign";
var content_f43_28_44481=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Risser sign for skeletal maturity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The iliac apophysis ossifies in a stepwise fashion from anterolateral to posteromedial along the iliac crest. The Risser sign is a visual grading of the degree to which the iliac apophysis has undergone ossification and fusion; it is used to assess skeletal maturity. Risser grade 0 corresponds to no ossification. As depicted above, grade 1 describes up to 25 percent ossification; grade 2 describes 26 to 50 percent ossification; grade 3 describes 51 to 75 percent ossification; grade 4 describes greater than 76 percent ossification; and grade 5 describes full bony fusion of the apophysis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_28_44481=[""].join("\n");
var outline_f43_28_44481=null;
var title_f43_28_44482="Calculator: Framingham 10 year risk of general cardiovascular disease in men (2008 paper)";
var content_f43_28_44482=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"Framingham08_M_form\" name=\"Framingham08_M_form\" onkeydown=\"clrResults();\" onkeyup=\"Framingham08_M_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Framingham 10 year risk of general cardiovascular disease in men (2008 paper)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          RiskFactors = (ln(Age) * 3.06117) + (ln(TotalChol) * 1.12370) - (ln(HDLChol) * 0.93263) +  (ln(SysBP) * SysBPFactor) + Cig + DM - 23.9802",
"         </span>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          Risk = 100 * (1 - 0.88936",
"          <sup>",
"           e",
"           <sup>",
"            (RiskFactors)",
"           </sup>",
"          </sup>",
"          )",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Age",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Age_param\" onblur=\"Framingham08_M_fx(); minMaxCheck();\" onchange=\"Framingham08_M_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Age_unit\" onchange=\"Framingham08_M_fx();\" style=\"width:105px;\">",
"              <option value=\"0.0833333333333333|0|mo\">",
"               mo",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|yr\">",
"               yr",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Sys BP",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Sys_BP_param\" onblur=\"Framingham08_M_fx(); minMaxCheck();\" onchange=\"Framingham08_M_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Sys_BP_unit\" onchange=\"Framingham08_M_fx();\" style=\"width:105px;\">",
"              <option value=\"0.00750063755419211|0|Pascal\">",
"               Pascal",
"              </option>",
"              <option value=\"760.002100178515|0|atm\">",
"               atm",
"              </option>",
"              <option value=\"750.063755419211|0|bar\">",
"               bar",
"              </option>",
"              <option value=\"0.735561538478802|0|cmH2O\">",
"               cmH2O",
"              </option>",
"              <option value=\"10|0|cmHg\">",
"               cmHg",
"              </option>",
"              <option value=\"22.4199156928339|0|ftH2O\">",
"               ftH2O",
"              </option>",
"              <option value=\"0.735561538478802|0|gm/sqcm\">",
"               gm/sqcm",
"              </option>",
"              <option value=\"1.86832630773616|0|inH2O\">",
"               inH2O",
"              </option>",
"              <option value=\"25.4000840071406|0|inHg\">",
"               inHg",
"              </option>",
"              <option value=\"7.50063755419211|0|kPa\">",
"               kPa",
"              </option>",
"              <option value=\"0.750063755419211|0|mbar\">",
"               mbar",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mmHg\">",
"               mmHg",
"              </option>",
"              <option value=\"51.7150957831416|0|psi\">",
"               psi",
"              </option>",
"              <option value=\"1|0|torr\">",
"               torr",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Total Chol",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Total_Chol_param\" onblur=\"Framingham08_M_fx(); minMaxCheck();\" onchange=\"Framingham08_M_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Total_Chol_unit\" onchange=\"Framingham08_M_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|mg/dL_Chol\">",
"               mg/dL",
"              </option>",
"              <option value=\"38.6697602474865|0|mmol/L_Chol\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              HDL Chol",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"HDL_Chol_param\" onblur=\"Framingham08_M_fx(); minMaxCheck();\" onchange=\"Framingham08_M_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"HDL_Chol_unit\" onchange=\"Framingham08_M_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|mg/dL_HDL\">",
"               mg/dL",
"              </option>",
"              <option value=\"38.6697602474865|0|mmol/L_HDL\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              On hypertension medication",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             &nbsp;&nbsp;",
"             <select class=\"medCalcFontSelect\" name=\"Sys_BP_Factor_pulldown\" onchange=\"Framingham08_M_fx();\" style=\"width:170px;\">",
"              <option value=\"1.93303\">",
"               No (1.93303)",
"              </option>",
"              <option value=\"1.99881\">",
"               Yes (1.99881)",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Cigarette smoker",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             &nbsp;&nbsp;",
"             <select class=\"medCalcFontSelect\" name=\"Cig_pulldown\" onchange=\"Framingham08_M_fx();\" style=\"width:170px;\">",
"              <option value=\"0\">",
"               No (0)",
"              </option>",
"              <option value=\"0.65451\">",
"               Yes (0.65451)",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Diabetes present",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             &nbsp;&nbsp;",
"             <select class=\"medCalcFontSelect\" name=\"DM_pulldown\" onchange=\"Framingham08_M_fx();\" style=\"width:170px;\">",
"              <option value=\"0\">",
"               No (0)",
"              </option>",
"              <option value=\"0.57367\">",
"               Yes (0.57367)",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Results:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Risk Factors",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Risk_Factors_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Risk",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Risk_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <select class=\"medCalcFontSelect\" name=\"Risk_unit\" onchange=\"Framingham08_M_fx();\" style=\"width:105px;\">",
"               <option selected=\"selected\" value=\"1|0|%\">",
"                %",
"               </option>",
"               <option value=\"100|0|fraction\">",
"                fraction",
"               </option>",
"               <option value=\"100|0|ratio\">",
"                ratio",
"               </option>",
"              </select>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"Framingham08_M_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option>",
"               1",
"              </option>",
"              <option selected=\"selected\">",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       This risk assessment tool is based on the Cox regression model of proportional hazards.",
"      </li>",
"      <li>",
"       Cardiovascular disease includes coronary disease, cerebrovascular disease, peripheral vascular arterial disease and heart failure.",
"      </li>",
"      <li>",
"       It may be applied to men who have had no prior history of cardiovascular disease.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        D'Agostino RB Sr, Vasan RS, Pencina MJ, et. al. General Cardiovascular Risk Profile for  Use in Primary Care. The Framingham Heart Study.",
"        <i>",
"         Circulation",
"        </i>",
"        . 2008 Jan 22.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_28_44482=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function Framingham08_M_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.Framingham08_M_form){",
"",
"",
"doCalc = true;",
"if (Age_param.value.indexOf(',') >= 0){ Age_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Age_unit.options[Age_unit.selectedIndex].value.split('|');",
"Age = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Sys_BP_param.value.indexOf(',') >= 0){ Sys_BP_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Sys_BP_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Sys_BP_unit.options[Sys_BP_unit.selectedIndex].value.split('|');",
"Sys_BP = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Total_Chol_param.value.indexOf(',') >= 0){ Total_Chol_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Total_Chol_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Total_Chol_unit.options[Total_Chol_unit.selectedIndex].value.split('|');",
"Total_Chol = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (HDL_Chol_param.value.indexOf(',') >= 0){ HDL_Chol_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(HDL_Chol_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = HDL_Chol_unit.options[HDL_Chol_unit.selectedIndex].value.split('|');",
"HDL_Chol = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"Sys_BP_Factor = parseFloat(Sys_BP_Factor_pulldown.options[Sys_BP_Factor_pulldown.selectedIndex].value);",
"Cig = parseFloat(Cig_pulldown.options[Cig_pulldown.selectedIndex].value);",
"DM = parseFloat(DM_pulldown.options[DM_pulldown.selectedIndex].value);",
"dp = decpts.options[decpts.selectedIndex].text;",
"Risk_Factors =  (ln(Age) * 3.06117) + (ln(Total_Chol) * 1.12370) - (ln(HDL_Chol) * 0.93263) +  (ln(Sys_BP) * Sys_BP_Factor) + Cig + DM - 23.9802;",
"",
"if (doCalc) Risk_Factors_param.value = fixDP(Risk_Factors, dp);",
"",
"",
"",
"Risk =  100 * (1 - power(0.88936, eTo(Risk_Factors)));",
"",
"unit_parts = Risk_unit.options[Risk_unit.selectedIndex].value.split('|');",
"if (doCalc) Risk_param.value = fixDP((Risk - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.Framingham08_M_form){",
"",
"if (Age_param.value && Age < 19) {",
"Age = 0;",
"Age_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Age is 19 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Age_param.value && Age > 80) {",
"Age_param.value = \"\";",
"clrResults();",
"Age = 0;",
"doCalc = false;",
"alert(\"The maximum value for Age is 80 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.Framingham08_M_form){",
"",
"Risk_Factors_param.value = '';",
"Risk_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f43_28_44482=null;
var title_f43_28_44483="Large basal cell carcinoma on ear";
var content_f43_28_44483=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Destructive basal cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large basal cell carcinoma causing destruction of the ear.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_28_44483=[""].join("\n");
var outline_f43_28_44483=null;
var title_f43_28_44484="Bronchocentric granulomatosis";
var content_f43_28_44484=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bronchocentric granulomatosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/28/44484/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/28/44484/contributors\">",
"     Harold R Collard, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/28/44484/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/28/44484/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/28/44484/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/28/44484/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/28/44484/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/28/44484/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchocentric granulomatosis is a destructive, granulomatous lesion of the bronchi and bronchioles that is generally believed to represent a nonspecific response to a variety of types of airway injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44484/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Approximately half of all cases are associated with asthma and allergic bronchopulmonary aspergillosis (ABPA), and among these patients, bronchocentric granulomatosis may represent a histopathologic manifestation of fungal hypersensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44484/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33545?source=see_link\">",
"     \"Allergic bronchopulmonary aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The remaining cases of bronchocentric granulomatosis are usually idiopathic, although associations with mycobacterial and fungal infection, rheumatologic disease, granulomatosis with polyangiitis (Wegener&rsquo;s), chronic granulomatous disease, glomerulonephritis, scleritis, diabetes insipidus, red cell aplasia, pulmonary echinococcosis, bronchogenic carcinoma, and influenza A virus have been reported (",
"    <a class=\"graphic graphic_table graphicRef62079 \" href=\"mobipreview.htm?19/42/20139\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44484/abstract/3,8-23\">",
"     3,8-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the lack of a clear clinical syndrome associated with bronchocentric granulomatosis, the presence of this lesion should generally be considered a",
"    <strong>",
"     nonspecific manifestation of lung injury",
"    </strong>",
"    , not an etiologic diagnosis.",
"   </p>",
"   <p>",
"    An overview of bronchocentric granulomatosis will be presented here. Pulmonary lymphomatoid granulomatosis, a different clinicopathological entity usually related to Epstein-Barr virus-associated lymphoma, and an approach to an adult with suspected interstitial lung disease, are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/20/41287?source=see_link\">",
"     \"Pulmonary lymphomatoid granulomatosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence and prevalence of bronchocentric granulomatosis are unknown. Bronchocentric granulomatosis is often divided clinically into two groups of patients based upon the presence or absence of asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44484/abstract/1,2,5\">",
"     1,2,5",
"    </a>",
"    ]. Patients with asthma tend to be younger (ages 20 to 40) and generally present with pulmonary symptoms such as cough, dyspnea or pleuritic chest pain. The nonasthmatic group is made up primarily of older patients, ranging in age from 30 to 70. Chest symptoms are rare, and nonspecific fatigue and malaise are more common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with bronchocentric granulomatosis associated with asthma, the laboratory evaluation is often consistent with ABPA. Typical findings include elevated peripheral blood eosinophil count, elevated total serum IgE, and circulating IgE antibodies to Aspergillus species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44484/abstract/1-3,5\">",
"     1-3,5",
"    </a>",
"    ]. Sputum gram stain and culture occasionally reveal Aspergillus or Candida species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44484/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33545?source=see_link\">",
"     \"Allergic bronchopulmonary aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27688?source=see_link\">",
"     \"Causes of pulmonary eosinophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence of fungal hypersensitivity is uncommon in nonasthmatic patients, although fungal elements can occasionally be isolated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44484/abstract/16\">",
"     16",
"    </a>",
"    ]. Most patients have a mild to moderately elevated erythrocyte sedimentation rate. Serologic evaluation for autoimmune disorders and vasculitides are generally unremarkable in the absence of systemic inflammatory disease (",
"    <a class=\"graphic graphic_table graphicRef62079 \" href=\"mobipreview.htm?19/42/20139\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiographic presentation of bronchocentric granulomatosis is varied, with single or multiple pulmonary nodules and areas of consolidation being reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44484/abstract/24\">",
"     24",
"    </a>",
"    ]. The upper lobes are more commonly involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44484/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Many patients will present with solitary pulmonary nodules suggestive of bronchogenic carcinoma; multiple nodules are less common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44484/abstract/24\">",
"     24",
"    </a>",
"    ]. However, one case series described the CT findings of bronchocentric granulomatosis as primarily upper lobe spiculated mass lesions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lobar consolidation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44484/abstract/25\">",
"     25",
"    </a>",
"    ]. One case report of FDG-PET scanning in bronchocentric granuloma reported intermediate activity without avid FDG uptake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44484/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=see_link\">",
"     \"High resolution computed tomography of the lungs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/31/44537?source=see_link\">",
"     \"Diagnostic evaluation and management of the solitary pulmonary nodule\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/34/14888?source=see_link\">",
"     \"Differential diagnosis and evaluation of multiple pulmonary nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchocentric granulomatosis is characterized by peribronchial and peribronchiolar necrotizing granulomatous inflammation (",
"    <a class=\"graphic graphic_picture graphicRef81739 graphicRef68811 \" href=\"mobipreview.htm?27/5/27738\">",
"     picture 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44484/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Bronchioles are more uniformly involved than the larger conducting airways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44484/abstract/1\">",
"     1",
"    </a>",
"    ]. Destruction of airway walls and adjacent parenchyma leads to granulomatous replacement of mucosa and submucosa by palisading, epithelioid, and multinucleated histiocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44484/abstract/1,2,5\">",
"     1,2,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lumens of affected airways may contain necrotic debris and closely mimic the appearance of necrotizing granulomas. In the setting of ABPA, bronchocentric granulomatosis is usually accompanied by mucoid impaction of bronchi and eosinophilic pneumonia in various combinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44484/abstract/1,5,27\">",
"     1,5,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bronchocentric granulomatosis does",
"    <strong>",
"     not",
"    </strong>",
"    typically involve the pulmonary arteries; in contrast, other conditions historically grouped under the heading of pulmonary angiitides and granulomatoses, such as granulomatosis with polyangiitis (Wegener&rsquo;s), necrotizing sarcoid granulomata, and pulmonary lymphomatoid granulomatosis, often include an angiocentric component [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44484/abstract/1,2,5\">",
"     1,2,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/20/41287?source=see_link\">",
"     \"Pulmonary lymphomatoid granulomatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchocentric granulomatosis is a nonspecific histopathological diagnosis made on the basis of surgical lung biopsy. It has been proposed that the diagnosis be reserved for isolated idiopathic cases and those cases in which it appears as a manifestation of ABPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44484/abstract/3\">",
"     3",
"    </a>",
"    ]. In all cases, a careful search for an underlying cause (eg, ABPA, mycobacterial and fungal infection, rheumatoid arthritis, granulomatosis with polyangiitis [Wegener&rsquo;s], bronchogenic carcinoma) should be undertaken (",
"    <a class=\"graphic graphic_table graphicRef62079 \" href=\"mobipreview.htm?19/42/20139\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients with a biopsy diagnosis of bronchocentric granulomatosis treatment is focused on the underlying or associated condition (see appropriate topic reviews). Many patients with unexplained or idiopathic bronchocentric granulomatosis improve without medical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44484/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Some patients require glucocorticoids to effect resolution, and a small number have recurrent or persistent disease requiring longer-term treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44484/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although patients who present with bronchocentric granulomatosis often undergo lobectomy at the time of diagnosis because of fear of bronchogenic carcinoma, there is no clear benefit to surgical excision, as glucocorticoid use and prognosis appear to be unaffected by this intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44484/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. There seems to be little difference in clinical course between asthmatic and nonasthmatic patients, although the former may require glucocorticoid treatment more frequently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44484/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bronchocentric granulomatosis is a destructive, granulomatous lesion of the bronchi and bronchioles. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33545?source=see_link\">",
"       \"Allergic bronchopulmonary aspergillosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bronchocentric granulomatosis is often divided clinically into two groups: patients with or without asthma. In all cases, a careful search for an underlying cause should be undertaken (",
"      <a class=\"graphic graphic_table graphicRef62079 \" href=\"mobipreview.htm?19/42/20139\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The chest radiographic presentation of bronchocentric granulomatosis is varied and includes solitary nodules, multiple nodules, and areas of consolidation. The upper lobes are more commonly involved than the lower lobes. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many patients with unexplained or idiopathic bronchocentric granulomatosis improve without medical therapy. A course of systemic glucocorticoids has resulted in improvement in a few case reports; a small number of patients have recurrent or persistent disease requiring longer-term glucocorticoid treatment. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/1\">",
"      Liebow AA. The J. Burns Amberson lecture--pulmonary angiitis and granulomatosis. Am Rev Respir Dis 1973; 108:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/2\">",
"      Clee MD, Lamb D, Clark RA. Bronchocentric granulomatosis: a review and thoughts on pathogenesis. Br J Dis Chest 1983; 77:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/3\">",
"      Myers JL. Bronchocentric granulomatosis. Disease or diagnosis? Chest 1989; 96:3.",
"     </a>",
"    </li>",
"    <li>",
"     Cordier, JF. Eosinophilic pneumonias. In: Interstitial Lung Disease, 4th ed, King TE Jr, Schwarz MI (Eds), B.C. Decker, Hamilton, ON, Canada 2003. p.679.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/5\">",
"      Katzenstein AL, Liebow AA, Friedman PJ. Bronchocentric granulomatosis, mucoid impaction, and hypersensitivity reactions to fungi. Am Rev Respir Dis 1975; 111:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/6\">",
"      Koss MN, Robinson RG, Hochholzer L. Bronchocentric granulomatosis. Hum Pathol 1981; 12:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/7\">",
"      Sulavik SB. Bronchocentric granulomatosis and allergic bronchopulmonary aspergillosis. Clin Chest Med 1988; 9:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/8\">",
"      Berendsen HH, Hofstee N, Kapsenberg PD, et al. Bronchocentric granulomatosis associated with seropositive polyarthritis. Thorax 1985; 40:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/9\">",
"      Bonafede RP, Benatar SR. Bronchocentric granulomatosis and rheumatoid arthritis. Br J Dis Chest 1987; 81:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/10\">",
"      Den Hertog RW, Wagenaar SS, Wastermann CJ. Bronchocentric granulomatosis and pulmonary echinococcosis. Am Rev Respir Dis 1982; 126:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/11\">",
"      Hellems SO, Kanner RE, Renzetti AD Jr. Bronchocentric granulomatosis associated with rheumatoid arthritis. Chest 1983; 83:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/12\">",
"      Rohatgi PK, Turrisi BC. Bronchocentric granulomatosis and ankylosing spondylitis. Thorax 1984; 39:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/13\">",
"      Rossi GP, Pavan E, Chiesura-Corona M, et al. Bronchocentric granulomatosis and central diabetes insipidus successfully treated with corticosteroids. Eur Respir J 1994; 7:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/14\">",
"      Wiedemann HP, Bensinger RE, Hudson LD. Bronchocentric granulomatosis with eye involvement. Am Rev Respir Dis 1982; 126:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/15\">",
"      Warren J, Pitchenik AE, Saldana MJ. Bronchocentric granulomatosis with glomerulonephritis. Chest 1985; 87:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/16\">",
"      Yano S, Shishido S, Kobayashi K, et al. Bronchocentric granulomatosis due to Aspergillus terreus in an immunocompetent and non-asthmatic woman. Respir Med 1999; 93:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/17\">",
"      Yousem SA. Bronchocentric injury in Wegener's granulomatosis: a report of five cases. Hum Pathol 1991; 22:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/18\">",
"      Myers JL, Katzenstein AL. Granulomatous infection mimicking bronchocentric granulomatosis. Am J Surg Pathol 1986; 10:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/19\">",
"      Fannin SW, Hagley MT, Seibert JD, Koenig TJ. Bronchocentric granulomatosis, acute renal failure, and high titer antineutrophil cytoplasmic antibodies: possible variants of Wegener's granulomatosis. J Rheumatol 1993; 20:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/20\">",
"      Houser SL, Mark EJ. Bronchocentric granulomatosis with mucus impaction due to bronchogenic carcinoma. An association with clinical relevance. Arch Pathol Lab Med 2000; 124:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/21\">",
"      Barrot E, Ortega-Calvo M, Borderas F, et al. Bronchocentric granulomatosis as a first clinical manifestation in an adult patient with p67phox deficiency. Respiration 1999; 66:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/22\">",
"      Moltyaner Y, Geerts WH, Chamberlain DW, et al. Underlying chronic granulomatous disease in a patient with bronchocentric granulomatosis. Thorax 2003; 58:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/23\">",
"      van der Klooster JM, Nurmohamed LA, van Kaam NA. Bronchocentric granulomatosis associated with influenza-A virus infection. Respiration 2004; 71:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/24\">",
"      Robinson RG, Wehunt WD, Tsou E, et al. Bronchocentric granulomatosis: roentgenographic manifestations. Am Rev Respir Dis 1982; 125:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/25\">",
"      Ward S, Heyneman LE, Flint JD, et al. Bronchocentric granulomatosis: computed tomographic findings in five patients. Clin Radiol 2000; 55:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/26\">",
"      Hurwitz LM, McAdams HP, Sporn TA. A 73-year-old woman with a cough. Chest 2005; 128:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44484/abstract/27\">",
"      Bosken CH, Myers JL, Greenberger PA, Katzenstein AL. Pathologic features of allergic bronchopulmonary aspergillosis. Am J Surg Pathol 1988; 12:216.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4322 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-49B032D4AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_28_44484=[""].join("\n");
var outline_f43_28_44484=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4322\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4322|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/42/43687\" title=\"picture 1A\">",
"      Bronchocentric granuloma Low",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/13/36054\" title=\"picture 1B\">",
"      Bronchocentric granuloma High",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4322|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/42/20139\" title=\"table 1\">",
"      Bronchocentric granulomatosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27688?source=related_link\">",
"      Causes of pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/31/44537?source=related_link\">",
"      Diagnostic evaluation and management of the solitary pulmonary nodule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/34/14888?source=related_link\">",
"      Differential diagnosis and evaluation of multiple pulmonary nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/20/41287?source=related_link\">",
"      Pulmonary lymphomatoid granulomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_28_44485="Molluscum in AIDS 2";
var content_f43_28_44485=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Molluscum contagiosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the double and \"giant lesions\" on the face of a patient with acquired immunodeficiency syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_28_44485=[""].join("\n");
var outline_f43_28_44485=null;
var title_f43_28_44486="Slit lamp examination";
var content_f43_28_44486=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Slit lamp examination",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/28/44486/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/28/44486/contributors\">",
"     Kevin J Knoop, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/28/44486/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/28/44486/contributors\">",
"     Allan B Wolfson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/28/44486/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/28/44486/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/28/44486/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/28/44486/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/28/44486/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The slit lamp is a binocular microscope that provides the examiner with a stereoscopic (ie, three dimensional) view of the eye (",
"    <a class=\"graphic graphic_figure graphicRef66058 \" href=\"mobipreview.htm?26/7/26739\">",
"     figure 1",
"    </a>",
"    ). It has changed little since its development by Goldman in 1937 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44486/abstract/1\">",
"     1",
"    </a>",
"    ]. The slit lamp allows the eye to be examined with a beam or &ldquo;slit&rdquo; of light (versus diffuse light) whose height and width can be adjusted. The slit of light, when directed at an angle, accentuates the anatomic structures of the eye, allowing close inspection. The slit lamp provides greater magnification (10 to 25 times) and illumination than most handheld devices (eg, Wood's lamp), which is necessary to diagnose a number of traumatic and nontraumatic disorders.",
"   </p>",
"   <p>",
"    A useful, interactive teaching program on vision care is available free from the University of Michigan Kellog Eye Center at",
"    <a class=\"external\" href=\"file://www.kellogg.umich.edu/theeyeshaveit\">",
"     www.kellogg.umich.edu/theeyeshaveit",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    This topic review will focus on the steps involved in the examination of the anterior segment of the eye using the basic slit lamp found in most primary and emergency care settings as well as indications and contraindications for its use. Specific diseases and injuries of the eye are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/19/2362?source=see_link\">",
"     \"Cataract in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20760?source=see_link\">",
"     \"Conjunctivitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34600?source=see_link\">",
"     \"Corneal abrasions and corneal foreign bodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17607?source=see_link\">",
"     \"Evaluation of the red eye\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/41/36504?source=see_link\">",
"     \"Retinal detachment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/16/26888?source=see_link\">",
"     \"Approach to the adult with acute persistent visual loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for the use of a slit lamp in the nonophthalmology setting include any acute condition that requires magnification to inspect the anterior segment of the eye (ie, lids, lashes, conjunctiva, cornea, anterior chamber, iris, and lens) or to facilitate ocular foreign body removal. Thus, it is well suited for diagnosing conditions such as corneal epithelial defect, keratoconjunctivitis, hyphema, hypopyon, lens dislocation, herpetic infections, iritis, or evaluation of the red eye.",
"   </p>",
"   <p>",
"    The slit lamp is less useful in diagnosing conditions of the posterior segment (ie, vitreous, fundus, optic disk) in the primary care office or emergency department. Such conditions include papilledema, vitreous hemorrhage, and retinal detachment. Diagnosis of such conditions with a slit lamp is feasible only if special attachments are available and the examiner has training and experience in their use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS AND PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no absolute contraindications for performing a slit lamp examination (SLE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44486/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the following points deserve emphasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a possible open globe injury should be examined with extreme caution, and clinicians must avoid placing pressure on the globe (eg, with lid eversion or foreign body [FB] removal) until this injury is ruled out. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8745?source=see_link\">",
"       \"Open globe injuries: Emergent evaluation and initial management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with exposure to caustic substances should be thoroughly irrigated and a normal pH of the conjunctival fluid documented before initiating a SLE.",
"     </li>",
"     <li>",
"      Caution is necessary during FB removal to avoid injury from a sudden patient movement or loss of orientation with the tool being used to remove the FB (eg, needle or burr drill).",
"     </li>",
"     <li>",
"      Children may be examined with parental assistance, reassurance, and special positioning in the slit lamp.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing a slit lamp examination (SLE) for an acute ocular condition are often uncomfortable or apprehensive. Use of a topical ophthalmic anesthetic agent (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/57/2963?source=see_link\">",
"     proparacaine",
"    </a>",
"    drops) reduces pain. Darkening the room and providing reassurance can also improve patient comfort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Patient counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific risks inherent in a SLE that require informed consent, but the purpose and methods of the SLE should be clearly explained. Potential complications of foreign body (FB) removal, such as globe perforation, while possible, have not been reported. Corneal epithelial defect (ie, CED or corneal abrasion) is another potential complication of FB removal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Materials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SLE is typically performed in a room with control of lighting and necessary materials. Portable and hand-held devices are now readily available which permit bedside evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44486/abstract/3\">",
"     3",
"    </a>",
"    ]. Materials needed for SLE may include anesthetic drops, cotton tipped applicator, cotton pledget,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    strip, burr drill or 18 gauge needle, gauze or tissue, eye rinse solution, and contact lens removal device (",
"    <a class=\"graphic graphic_table graphicRef66719 \" href=\"mobipreview.htm?18/14/18667\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examiner must be familiar with the anatomy of the eye's anterior chamber (",
"    <a class=\"graphic graphic_figure graphicRef73347 \" href=\"mobipreview.htm?43/45/44752\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef57690 \" href=\"mobipreview.htm?41/35/42549\">",
"     figure 3",
"    </a>",
"    ). The tangential slit of light projected by the slit lamp allows a three dimensional view of anatomic structures that are not normally appreciated with diffuse lighting even with magnification. These include the epithelium, stroma, and endothelium of the cornea; aqueous humor; and lens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     General considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before performing a slit lamp examination (SLE), obtain a relevant history and perform an external ocular examination, including visual acuity and cranial nerve assessment. Document your findings, including the indication for SLE.",
"   </p>",
"   <p>",
"    Patients undergoing a SLE may be sensitive to light (photophobia). Dim the ambient room light and use maximal illumination sparingly during the exam to alleviate discomfort. Allay patient fears by providing a concise introduction to the procedure. This is especially important with any maneuver that involves physical contact with the eye, whether it consists of instilling medications, rinsing the eye, or using a tool to measure pH or to remove a foreign body (FB). Give clear instructions about what the patient is to do (eg, eye movement, positioning, blinking) and what they are likely to feel. Position children in a family member's lap with the chin brace adjusted for their height.",
"   </p>",
"   <p>",
"    If the examiner wears corrective lenses, we recommend that these be worn during the exam. If not, pay careful attention to focusing. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Focusing the slit lamp'",
"    </a>",
"    below.) Inquire about the use of contact lenses",
"    <strong>",
"     before",
"    </strong>",
"    instilling any medication into the eye.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     Fluorescein",
"    </a>",
"    will permanently stain contact lenses; remove contact lenses before applying fluorescein. If an intraocular FB (globe penetration) is suspected, protect the eye with a nonpressure shield and immediately consult an ophthalmologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Analgesia and sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use a topical anesthetic to facilitate the SLE when eye pain or blepharospasm interferes. Before instilling the agent, inform the patient that all topical agents cause transient pain before they take effect.",
"   </p>",
"   <p>",
"    We suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/57/2963?source=see_link\">",
"     proparacaine",
"    </a>",
"    be used for topical anesthesia during the procedure. A prospective randomized double-masked protocol comparing proparacaine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/12/36032?source=see_link\">",
"     tetracaine",
"    </a>",
"    in 23 volunteers found that proparacaine caused less pain and longer anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44486/abstract/4\">",
"     4",
"    </a>",
"    ]. An in vitro study found that rabbit corneal epithelial cells treated with tetracaine exhibited greater cytotoxicity than cells treated with proparacaine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44486/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anesthetic agents typically degrade more quickly if left at room temperature for more than one week. Discard agents that turn from clear to light brown. Whenever possible, use unit dose vials to reduce the risk of infection. While commonly used for pain control during the period immediately following photorefractive keratectomy (PRK), topical anesthetic agents are not currently recommended for long-term pain control in the primary care (PC) or emergency department (ED) setting. They may delay wound healing by decreasing the tear film stability and tear break-up times through disruption of the surface microvilli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44486/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Set up and patient positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial step in performing the SLE is to ensure that the slit lamp is configured correctly for the exam, the examiner, and the patient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Place adjunct material or equipment within reach (",
"      <a class=\"graphic graphic_table graphicRef66719 \" href=\"mobipreview.htm?18/14/18667\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Adjust the examiner chair height for comfort.",
"     </li>",
"     <li>",
"      Loosen the locking nut on the slit lamp assembly to allow free movement (",
"      <a class=\"graphic graphic_picture graphicRef54895 \" href=\"mobipreview.htm?0/46/737\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Set each ocular lens to \"0\" (",
"      <a class=\"graphic graphic_figure graphicRef78421 \" href=\"mobipreview.htm?7/10/7328\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Adjust interpupillary distance by grasping the binocular housing attached to the objective lens, and pull apart or push together the eyepieces to make the adjustment (",
"      <a class=\"graphic graphic_figure graphicRef66058 \" href=\"mobipreview.htm?26/7/26739\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Position the patient in the chin rest, and instruct the patient to keep his or her forehead in contact with the headrest at all times during the SLE.",
"     </li>",
"     <li>",
"      Adjust the height of the table for patient comfort.",
"     </li>",
"     <li>",
"      Adjust the chin rest height so that the pupils are aligned with the marker (",
"      <a class=\"graphic graphic_picture graphicRef64137 \" href=\"mobipreview.htm?10/52/11072\">",
"       picture 2",
"      </a>",
"      ). This places the eye within the range of the vertical height adjustment on the slit lamp.",
"     </li>",
"     <li>",
"      Patients may hold the slit lamp hand rest or rest their hands in their lap.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Focusing the slit lamp",
"    </span>",
"    &nbsp;&mdash;&nbsp;This step is crucial for viewing subtleties such as cells in the anterior chamber or appreciating the depth of a corneal lesion. After preparing equipment and positioning the patient (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Set up and patient positioning'",
"    </a>",
"    above), perform the following steps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adjust the slit lamp beam for a tall, narrow vertical beam of white light. The slit width should be adjusted to make the beam as narrow as possible without causing illumination to decrease (",
"      <a class=\"graphic graphic_picture graphicRef77853 graphicRef52336 \" href=\"mobipreview.htm?16/52/17222\">",
"       picture 3A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Direct the beam onto the bridge of the patient's nose at an approximate angle of 45 degrees.",
"     </li>",
"     <li>",
"      Move the entire assembly (coarse focus) in and out along the axis of the light while watching the beam of light. Do not view the beam through the objective lenses yet rather, view directly by looking around the side of the objectives. The goal is to bring the slit of light into crisp sharp focus.",
"     </li>",
"     <li>",
"      Once a crisp focused beam is evident externally, look through the objective lenses and confirm that the microscope is on low power.",
"     </li>",
"     <li>",
"      Adjust the joystick (fine focus) in and out to obtain a crisp slit. Close each eye and obtain a crisp image, one eye at a time, by adjusting the objective lenses (oculars). Only a slight adjustment should be needed for emmetropic eyes or those with corrected visual acuity. A larger adjustment will be needed for those who have uncorrected myopic or hyperopic eyes or elect not to wear their corrective lenses. Once focus is achieved, the SLE can be performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To obtain rapid consistent focus from one exam to the next on the same slit lamp, the examiner may wish to determine their individual refractive state with the use of the focusing rod (found with most slit lamps). To do this, perform the following steps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insert the focusing rod in the pivot post in front of the microscope (",
"      <a class=\"graphic graphic_picture graphicRef72486 \" href=\"mobipreview.htm?10/12/10447\">",
"       picture 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Direct the slit beam to the center of the flat face of the rod and set beam 1 to 2 mm in width.",
"     </li>",
"     <li>",
"      Focus the eyepieces individually on the slit beam, starting the eyepiece from the positive side of the scale and stopping at the point at which the image first appears sharply focused.",
"     </li>",
"     <li>",
"      Note the setting on the eyepiece scale, and always use this setting when using the slit lamp.",
"     </li>",
"     <li>",
"      Remove focusing rod.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Performing the exam",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examine the following areas: lids, lashes, conjunctiva, cornea, anterior chamber, and lens. The SLE can also be used to perform applanation tonometry (not discussed here). Once the patient is in position, equipment is set up, and the slit lamp is focused and set to low power. The exam is performed as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Confirm that the light angle is approximately 45 degrees projecting temporal to nasal.",
"     </li>",
"     <li>",
"      While looking through the oculars with a tall, narrow, focused light beam, slide the entire assembly forward and temporally until the lids come into focus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Lower lid/lashes/conjunctiva",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use the vertical height adjustment to view the lower lid. Use a cotton tipped applicator (CTA) to facilitate lid movement for this portion of the exam.",
"     </li>",
"     <li>",
"      Use subtle forward and back movements of the joystick to focus on the lower lid while sliding the entire assembly horizontally to view the lower lid and lashes.",
"     </li>",
"     <li>",
"      Use the CTA to visualize the palpebral conjunctiva by placing it horizontally beneath the lower lid and rolling it downward while instructing the patient to look up. This everts the lower lid and allows examination of the palpebral conjunctiva.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Upper lid/lashes/conjunctiva",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Instruct the patient to look down.",
"     </li>",
"     <li>",
"      Use the vertical height adjustment to center the beam of light on the upper lid and lashes.",
"     </li>",
"     <li>",
"      Use subtle forward and back movements of the joystick to focus on the upper lid while sliding the entire assembly horizontally to view the upper lid and lashes.",
"     </li>",
"     <li>",
"      If examination of the upper lid palpebral conjunctiva is indicated (FB suspected), eversion of the lid can be performed as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Place the CTA horizontally along the palpebral fold of the upper lid. Roll the CTA slightly to evert the eyelashes so that they may be more easily grasped. Grasp the upper eyelashes with your free hand, pull slightly away, then pull upward, using the CTA as a fulcrum.",
"     </li>",
"     <li>",
"      Hold the upper lid in an everted position with your thumb while the slit lamp is moved horizontally to pan across the now exposed palpebral conjunctiva. Use subtle in and out movements of the joystick for focus. When examination of this segment is complete, release the upper lid, and instruct the patient to look up and blink. This will return the lid to its normal position.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Cornea",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use the vertical height adjustment to center the beam on the central cornea at either the nasal or temporal limbus (edge of the cornea).",
"     </li>",
"     <li>",
"      Set the magnification to low power.",
"     </li>",
"     <li>",
"      Use subtle forward and back movements of the joystick to focus on the corneal epithelium while sliding the entire assembly left and right horizontally to view the cornea. As the cornea is curved in two dimensions, multiple adjustments will need to be made in order to visualize the entire corneal surface. The examiner must not allow the focus to wander from the corneal epithelium. Often, a small corneal epithelial defect (ie, CED or corneal abrasion) can be seen prior to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      staining.",
"     </li>",
"     <li>",
"      If a lesion is seen, switch to high power to examine the lesion more closely. Use subtle forward and back movements of the joystick to bring the lesion into focus and to appreciate its size and depth as well as any surrounding infiltrate or corneal edema. The angle of the slit lamp beam may be adjusted to bring the lesion into better view.",
"     </li>",
"     <li>",
"      Under high power, the corneal stroma and endothelium is visualized for infiltrate, edema, or keratic precipitates (collections of red or white blood cells on the endothelial surface). Wrinkling of the corneal endothelium is evidence of corneal edema. The focal point of the beam must be placed precisely on the endothelium for these findings to be appreciated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Fluorescein examination for corneal abrasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    examination is commonly performed when a corneal abrasion (or corneal epithelial defect, CED) is suspected. It is performed as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wet a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      strip with a single drop of liquid (eg, saline or topical anesthetic).",
"     </li>",
"     <li>",
"      Pull the lower lid down while instructing the patient to look up.",
"     </li>",
"     <li>",
"      Touch the tip of the strip to the lower conjunctival fornix, taking care to avoid abrading the cornea. Topical anesthesia is not required if done gently.",
"     </li>",
"     <li>",
"      Have the patient blink. A greenish hue overlying the cornea indicates adequate",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      instillation. This is best appreciated while watching the slit lamp beam directed on the cornea with the naked eye. If no green hue is seen, repeat the application. The goal is to apply the minimum needed amount of fluorescein; too much will obscure subtle CEDs. If too much is applied, rinse the eye and continue with the next step of the exam.",
"     </li>",
"     <li>",
"      Select the cobalt blue filter and widen the slit beam by turning the width adjustment.",
"     </li>",
"     <li>",
"      Position the patient properly in the slit lamp and observe the cornea under low power as described above.",
"     </li>",
"     <li>",
"      Use high power as needed to identify subtle (punctate) or dendritic (herpetic) lesions (",
"      <a class=\"graphic graphic_picture graphicRef75851 \" href=\"mobipreview.htm?35/33/36383\">",
"       picture 5",
"      </a>",
"      ) that fluoresce. The appearance of a CED often gives the examiner a clue to its etiology (",
"      <a class=\"graphic graphic_picture graphicRef54709 \" href=\"mobipreview.htm?3/26/3488\">",
"       picture 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef72088 \" href=\"mobipreview.htm?32/2/32800\">",
"       picture 7",
"      </a>",
"      ). Infiltrates that are seen under white light, but not seen with the cobalt blue filter are subepithelial and are not CEDs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Seidel's test",
"    </span>",
"    &nbsp;&mdash;&nbsp;This test uses",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    to examine for suspected microperforation of the globe.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apply topical anesthetic agent.",
"     </li>",
"     <li>",
"      Select the cobalt blue filter and widen the slit beam maximally by turning the width adjustment.",
"     </li>",
"     <li>",
"      Wet a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      strip with several drops of liquid (eg, saline or topical anesthetic).",
"     </li>",
"     <li>",
"      Touch the end of the strip to the eye in a painting motion to maximize contact between the eye and the strip.",
"     </li>",
"     <li>",
"      Ensure proper positioning of the patient in the slit lamp and observe the cornea under low power as described above. A small perforation will cause a clearing of the dense",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      , which will appear to be streaming away from the perforation site (",
"      <a class=\"graphic graphic_picture graphicRef67497 \" href=\"mobipreview.htm?11/45/11998\">",
"       picture 8",
"      </a>",
"      ). This is a positive Seidel's test indicating perforation of the globe.",
"     </li>",
"     <li>",
"      If the Seidel's test is positive, protect the eye with a shield, and consult an ophthalmologist immediately.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Cells and flare",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Darken the room completely to reduce ambient light.",
"     </li>",
"     <li>",
"      Adjust the beam height and width to short and slightly wide.",
"     </li>",
"     <li>",
"      Use the vertical height adjustment to center the beam on the central cornea.",
"     </li>",
"     <li>",
"      Move the joystick forward to focus on the iris then backward to focus on the corneal epithelium. Repeat this several times to get a feel for the range of movement required between these two focus points.",
"     </li>",
"     <li>",
"      Use about one half of the movement needed above to place the focal point in the middle of the anterior chamber.",
"     </li>",
"     <li>",
"      Observe for the presence of flare (like the headlight beam in the fog) or cells (tiny &ldquo;sparkles&rdquo; of light) floating through the currents of the anterior chamber. WBC's have white reflections, while RBC's in the anterior chamber have a reddish brown reflection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     FB removal",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apply adequate topical anesthesia.",
"     </li>",
"     <li>",
"      Emphasize to the patient the need for maximal compliance with positioning during the procedure.",
"     </li>",
"     <li>",
"      Reassure the patient (complications and perforation are extremely unlikely).",
"     </li>",
"     <li>",
"      Grasp the removal device (burr drill or needle with syringe or CTA attached) with the hand on the same side as the foreign body (eg, use right hand for left FB).",
"     </li>",
"     <li>",
"      Rest your hand on the patient's cheek to stabilize the hand during the procedure, but ensure that the removal device is held well away from the eye.",
"     </li>",
"     <li>",
"      While directly observing the removal device, position it in the light beam and move slowly toward the eye, stopping about 3 to 5 mm in front of the eye.",
"     </li>",
"     <li>",
"      Observe the device through the objective lenses of the slit lamp and slowly advance it under magnification until the removal device and area of the FB is clear and in focus.",
"     </li>",
"     <li>",
"      Use the removal device to scrape the FB tangential to the cornea for removal (",
"      <a class=\"graphic graphic_figure graphicRef54663 \" href=\"mobipreview.htm?14/22/14703\">",
"       figure 5",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44486/abstract/8\">",
"       8",
"      </a>",
"      ]. Remove only what is easily scraped away. There is no need to aggressively scrape or use a puncture motion on the cornea. Residual material, such as a rust ring (",
"      <a class=\"graphic graphic_picture graphicRef52592 \" href=\"mobipreview.htm?36/54/37729\">",
"       picture 9",
"      </a>",
"      ), can easily be removed in 24 hours as the small area of surrounding tissue becomes necrotic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Exercise for viewing anterior chamber cells",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Follow instructions for patient position, equipment set up, and slit lamp focus as listed above.",
"     </li>",
"     <li>",
"      Set slit lamp to high power with a tall narrow beam.",
"     </li>",
"     <li>",
"      Completely darken the room to reduce ambient light.",
"     </li>",
"     <li>",
"      Use the vertical height adjustment to center the beam on the nasal or temporal limbus (edge of the cornea). Look for a vessel in this area that shows some movement or shimmers with each systole.",
"     </li>",
"     <li>",
"      Use subtle forward and back movements of the joystick to focus on a segment of the vessel that allows visualization of the red blood cells (RBC) in the vessel. RBCs may be seen in rouleaux (stacked like coins), or individually as they course through the vessel with each systole. This is usually the maximum resolution that can be obtained with a primary care slit lamp.",
"      <br/>",
"      <br/>",
"      The examiner must have the skills to obtain this resolution in order to visualize important findings on SLE. This exercise provides practice at obtaining these skills. With instruction, most attentive students can perform this exercise during the first session using a slit lamp.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious complications during slit lamp examination are rare and include globe perforation during foreign body (FB) removal and allergic reaction to medication placed in the eye. Mild complications include iatrogenic corneal epithelial defect (ie, CED or corneal abrasion) when removing a FB or contact lens and minor irritation from medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The slit lamp examination (SLE) does not require follow-up care, but acute eye conditions often do. Appropriate instructions should be given to the patient that address the diagnosis and treatment of the condition. Any patient who has the eye manipulated (eg, foreign body or contact lens removal) should be given precautions to return for worsening pain, photophobia, eye redness, and decreased visual acuity. Medication for pain and possibly lubrication should be given until healing occurs. Follow-up is generally advised within 24 hours. Most clinicians place patients with a corneal epithelial defect (ie, CED or corneal abrasion) on topical antibiotics, though no randomized controlled studies exist to support this practice. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34600?source=see_link\">",
"     \"Corneal abrasions and corneal foreign bodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H313223361\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the nonophthalmology setting, the slit lamp examination (SLE) is useful for diagnosing many acute conditions involving the anterior segment of the eye or to facilitate ocular foreign body removal. Such conditions may include corneal epithelial defect, keratoconjunctivitis, hyphema, hypopyon, lens dislocation, herpetic infections, iritis, or the red eye. The slit lamp is less useful in diagnosing conditions of the posterior segment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no absolute contraindications for performing a SLE. However, patients with a possible open globe injury should be examined with extreme caution until such injury is ruled out, and patients with exposure to caustic substances should be thoroughly irrigated and a normal pH of the conjunctival fluid obtained before initiating a SLE. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Contraindications and precautions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients undergoing SLE for an acute ocular condition are often uncomfortable or apprehensive. Use of a topical ophthalmic anesthetic agent (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/57/2963?source=see_link\">",
"       proparacaine",
"      </a>",
"      drops) reduces pain. A list of materials needed for SLE is provided (",
"      <a class=\"graphic graphic_table graphicRef66719 \" href=\"mobipreview.htm?18/14/18667\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Preparation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Analgesia and sedation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The steps involved in setting up the slit lamp and performing the examination are described in detail in the text. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H313223354\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;This article represents the views of the author and UpToDate, and does not reflect the official policy or position of the U.S. Navy or the U.S. Government.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Tate GW, Safir A. The slit lamp: History, principles, and practice. In: Clinical Opthalmology, Duane TD (Ed), Harper &amp; Row, New York 1981. Vol 1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44486/abstract/2\">",
"      Knoop K, Trott A. Ophthalmologic procedures in the emergency department--Part I: Immediate sight-saving procedures. Acad Emerg Med 1994; 1:408.",
"     </a>",
"    </li>",
"    <li>",
"     Hand-Held Portable Slit Lamp from Reichert. Review of Ophthalmology 2006. www.revophth.com/index.asp?page=1_1008.htm (Accessed on September 07, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44486/abstract/4\">",
"      Bartfield JM, Holmes TJ, Raccio-Robak N. A comparison of proparacaine and tetracaine eye anesthetics. Acad Emerg Med 1994; 1:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44486/abstract/5\">",
"      Grant RL, Acosta D. Comparative toxicity of tetracaine, proparacaine and cocaine evaluated with primary cultures of rabbit corneal epithelial cells. Exp Eye Res 1994; 58:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44486/abstract/6\">",
"      Rosenwasser GO. Complications of topical ocular anesthetics. Int Ophthalmol Clin 1989; 29:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44486/abstract/7\">",
"      Brilakis HS, Deutsch TA. Topical tetracaine with bandage soft contact lens pain control after photorefractive keratectomy. J Refract Surg 2000; 16:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44486/abstract/8\">",
"      Knoop K, Trott A. Ophthalmologic procedures in the emergency department--Part III: Slit lamp use and foreign bodies. Acad Emerg Med 1995; 2:224.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 259 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.146-C1CFDD43C6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_28_44486=[""].join("\n");
var outline_f43_28_44486=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H313223361\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CONTRAINDICATIONS AND PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Patient counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Materials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      General considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Analgesia and sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Set up and patient positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Focusing the slit lamp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Performing the exam",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Lower lid/lashes/conjunctiva",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Upper lid/lashes/conjunctiva",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Cornea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Fluorescein examination for corneal abrasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Seidel's test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Cells and flare",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      FB removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Exercise for viewing anterior chamber cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H313223361\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H313223354\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/259\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/259|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/7/26739\" title=\"figure 1\">",
"      Slit lamp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/45/44752\" title=\"figure 2\">",
"      Anatomy ant segment struct",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/35/42549\" title=\"figure 3\">",
"      Eye anatomy in cross section",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/10/7328\" title=\"figure 4\">",
"      Slit lamp ocular lens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/22/14703\" title=\"figure 5\">",
"      Foreign body removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/259|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/46/737\" title=\"picture 1\">",
"      Slit lamp lock nut",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/52/11072\" title=\"picture 2\">",
"      Slit lamp chin rest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/9/37008\" title=\"picture 3A\">",
"      Slit lamp beam height",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/55/17265\" title=\"picture 3B\">",
"      Slit lamp beam width",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/12/10447\" title=\"picture 4\">",
"      Slit lamp focusing rod",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/33/36383\" title=\"picture 5\">",
"      Slit lamp keratitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/26/3488\" title=\"picture 6\">",
"      Linear corneal abrasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/2/32800\" title=\"picture 7\">",
"      Welders keratitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/45/11998\" title=\"picture 8\">",
"      Siedel test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/54/37729\" title=\"picture 9\">",
"      Rust ring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/259|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/14/18667\" title=\"table 1\">",
"      Slit lamp materials",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/16/26888?source=related_link\">",
"      Approach to the adult with acute persistent visual loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/19/2362?source=related_link\">",
"      Cataract in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20760?source=related_link\">",
"      Conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34600?source=related_link\">",
"      Corneal abrasions and corneal foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17607?source=related_link\">",
"      Evaluation of the red eye",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8745?source=related_link\">",
"      Open globe injuries: Emergent evaluation and initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/41/36504?source=related_link\">",
"      Retinal detachment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_28_44487="Use of biochemical markers of bone turnover in osteoporosis";
var content_f43_28_44487=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of biochemical markers of bone turnover in osteoporosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/28/44487/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/28/44487/contributors\">",
"     Harold N Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/28/44487/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/28/44487/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/28/44487/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/28/44487/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/28/44487/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of biochemical bone turnover markers (BTMs) in clinical trials has been helpful in understanding the mechanism of action of therapeutic agents. However, their role in the care of individual patients is not well established. Biologic and laboratory variability in BTM values have confounded their widespread use in clinical practice (",
"    <a class=\"graphic graphic_table graphicRef77322 \" href=\"mobipreview.htm?9/35/9789\">",
"     table 1",
"    </a>",
"    ). BTMs have little value for the diagnosis of osteoporosis, because dual-energy x-ray absorptiometry (DXA) is far superior for this purpose. However, markers of bone turnover give some indication about the future risk for bone loss and fractures. More importantly, they are useful in monitoring the efficacy of antiresorptive therapy in patients with osteoporosis.",
"   </p>",
"   <p>",
"    This topic will review these issues. The rationale for the use of biochemical markers and the meaning of the different markers are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/33/42519?source=see_link\">",
"     \"Bone physiology and biochemical markers of bone turnover\"",
"    </a>",
"    .) The use of BTMs in other bone disorders is also reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2234?source=see_link\">",
"     \"Investigational biologic markers in the diagnosis and assessment of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=see_link\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean values for biochemical markers of bone turnover are higher in patients with osteoporosis than in matched normal subjects. As an example, the mean urinary excretion of deoxypyridinoline crosslinks (DPD, a marker of bone resorption) is 20 to 100 percent higher in patients with osteoporosis than in normal subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The results of measurements of other markers are similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/1-3,5\">",
"     1-3,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, bone mineral density in patients with osteoporosis is inversely related to the levels of markers of bone turnover. One study, for example, found a highly significant correlation between serum osteocalcin concentrations (a marker of bone formation) and bone mineral density of the spine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/6\">",
"     6",
"    </a>",
"    ]. Another report divided subjects into quintiles according to the urinary excretion of cross-linked N-telopeptides (NTX) of type I collagen, a marker of bone resorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/7\">",
"     7",
"    </a>",
"    ]. There was an inverse relationship between the quintile of urinary N-telopeptide excretion and mean bone mineral density (",
"    <a class=\"graphic graphic_figure graphicRef58794 \" href=\"mobipreview.htm?15/56/16271\">",
"     figure 1",
"    </a>",
"    ). These findings are consistent with the concept that osteoporosis is characterized by an increase in both bone formation and resorption. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=see_link\">",
"     \"Pathogenesis of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these general trends, biochemical markers are not useful in making the diagnosis of osteoporosis because the values in normal subjects and patients with osteoporosis overlap substantially (",
"    <a class=\"graphic graphic_figure graphicRef80253 \" href=\"mobipreview.htm?20/27/20925\">",
"     figure 2",
"    </a>",
"    ). For this reason, we do not recommend measurements of markers of bone turnover to make a diagnosis of osteoporosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREDICTING BONE LOSS AND FRACTURE RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient's current bone density is an important predictor of fracture risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. However, a single measurement indicates only current density, not the anticipated rate of bone loss. Patients with a given bone density who are losing bone more rapidly will have a higher fracture risk.",
"   </p>",
"   <p>",
"    Several studies have demonstrated that markers of bone turnover may be useful in predicting rates of bone loss (",
"    <a class=\"graphic graphic_figure graphicRef71125 \" href=\"mobipreview.htm?36/42/37550\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/10-16\">",
"     10-16",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective cohort study of 1044 elderly women, subjects with the highest markers of bone turnover over five years suffered the greatest bone loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the control arm of a trial of 236 postmenopausal women randomly assigned to postmenopausal hormone therapy and calcium versus calcium alone (control), women with the highest quartile value of NTX throughout the study had the greatest bone loss compared with women with the lowest quartile value [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a subset of 682 men participating in the Osteoporotic Fractures in Men (MrOS) study, higher baseline levels of bone turnover (type I collagen N-propeptide [PINP], beta C-terminal cross-linked telopeptide of type I collagen [betaCTX], and TRACP5b) were associated with greater hip bone loss over five years of follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, several [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/18-25\">",
"     18-25",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/17,26,27\">",
"     17,26,27",
"    </a>",
"    ], studies have shown that elevated BTMs are associated with increased risk of vertebral and nonvertebral fracture in both postmenopausal women and men, independent of BMD. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the EPIDOS study, elderly women with urinary C-terminal collagen crosslink (CTX) or free DPD excretion above the normal limits for young women had twice the risk of hip fracture as compared with other women (",
"      <a class=\"graphic graphic_figure graphicRef52905 \" href=\"mobipreview.htm?38/47/39677\">",
"       figure 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among osteopenic women followed in the Os des Femmes de Lyon (OFELY) prospective cohort study, low BMD, increased BTMs (bone specific alkaline phosphatase [BALP]), and prior fracture were independently associated with an increased fracture risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, in a subset of placebo patients in the Multiple Outcomes of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       Raloxifene",
"      </a>",
"      (MORE) study, none of the BTMs (BALP, osteocalcin or urinary C-telopeptide) that were measured influenced fracture risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although most epidemiologic studies show that BTMs are an independent risk factor for fracture, for a given BTM value, individual rates of bone loss and fracture are variable, limiting the usefulness of BTMs in predicting an individual's fracture risk. Thus, there is currently no consensus on a role for BTMs in determining candidates for osteoporosis therapy. The decision to treat such patients should be based upon fracture risk assessment using BMD and clinical risk factors. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link\">",
"     \"Osteoporotic fracture risk assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Candidates for therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of osteoporosis in men\", section on 'Candidates for therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     BTMs AND OSTEOPOROSIS THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of osteoporosis therapy on BTMs depends upon the mechanism of action of the specific therapy. Antiresorptive agents, such as bisphosphonates, cause a rapid decrease in markers of bone resorption. Bone formation markers are stable and then decrease. In contrast, anabolic agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/22/6501?source=see_link\">",
"     recombinant human parathyroid hormone",
"    </a>",
"    , cause a rapid increase in bone formation markers, followed by an increase in markers of bone resorption. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link&amp;anchor=H4#H4\">",
"     \"Parathyroid hormone therapy for osteoporosis\", section on 'Bone remodeling unit'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Assessment of baseline and post-therapy BTMs may be useful for monitoring patients taking osteoporosis therapy for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The early change in BTMs following therapy has been shown to be predictive of improvement in bone mineral density and anti-fracture efficacy.",
"     </li>",
"     <li>",
"      Demonstrating such changes reflects the degree of patient compliance and improves patient persistence with therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Efficacy of osteoporosis therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials have shown an association between the decrease in BTMs after initiation of antiresorptive therapy and long-term anti-fracture efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/28-33\">",
"     28-33",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a post-hoc analysis of the Fracture Intervention Trial, the greater the decline in BALP and N-terminal propeptide of type 1 procollagen (PINP) after initiation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      , the greater the decrease in spine and hip fracture [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the MORE trial, fracture risk reduction with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      therapy correlated better with changes in markers of bone turnover than with improvements in bone mineral density [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      vertebral fracture trials, the greatest decrease in fracture risk was among subjects with a decrease in urine NTX of more than 40 percent and urine CTX of more than 60 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/29\">",
"       29",
"      </a>",
"      ]. In a subsequent analysis of the same data, measurement of a single urine CTX value while taking risedronate was predictive of fracture reduction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/32\">",
"       32",
"      </a>",
"      ]. CTX values less than or equal to the mean for premenopausal women were associated with the lowest fracture risk, and further suppression of turnover did not result in further reduction of fracture risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, a reduction in BTMs after initiation of antiresorptive therapy is associated with a decrease in fracture. However, the optimal threshold for each marker is not well established. Based upon the above trials, a successful reduction in BTMs could be defined as an approximately 50 percent (urine markers) or 30 percent (serum markers) decline, or as reducing the BTM to within the lower one half of the reference range for premenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/29,32\">",
"     29,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This approach (evaluating a reduction in BTMs) is only useful with antiresorptive therapy, not with recombinant PTH (markers would increase). An increase in markers of bone formation (C-terminal propeptide of type 1 procollagen [PICP] and BALP) one month after initiation of PTH has been associated with improvement in bone structure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link&amp;anchor=H43#H43\">",
"     \"Parathyroid hormone therapy for osteoporosis\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data on long-term outcomes when BTMs are decreased below the reference interval. Some investigators have hypothesized that such oversuppression of bone turnover may interfere with normal repair of microdamage and increased skeletal fragility. This topic is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H50#H50\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Atypical femur fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Improving compliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term compliance with anti-osteoporosis therapy is poor. There are some data to suggest that sharing results of BTMs with patients improves compliance with therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. In addition, there are occasionally patients with osteoporosis who have difficulty tolerating treatment or are reluctant to take treatment. In this population, measurement of a marker of bone turnover that shows a value above the upper limits for premenopausal women puts such patients at especially high risk of bone loss and fracture, which might convince the reluctant patient that treatment is especially beneficial for them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;While there are a number of approaches to monitoring the response to antiresorptive therapy, there is no consensus on the optimal approach, and there are no prospective trials to define how best to incorporate markers into monitoring strategies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H33#H33\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Guidelines for monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One approach is to monitor bone density at baseline and again after two years of therapy. However, this approach would not detect failure of therapy for a long time.",
"     </li>",
"     <li>",
"      A second approach involves measuring bone density and a marker of bone turnover at baseline, followed by a repeat measurement of the marker after three to six months of antiresorptive therapy. A decrease of greater than 50 or 30 percent in urinary NTX excretion or serum carboxy-terminal collagen crosslinks (CTX), respectively, provides evidence of compliance and drug efficacy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/37-40\">",
"       37-40",
"      </a>",
"      ]; in such patients, therapy should be continued for two years, when bone density can be measured again.",
"      <br/>",
"      <br/>",
"      In contrast, a decrease in markers of less than 50 or 30 percent may not necessarily indicate treatment failure, since many patients with small changes in turnover have stable BMD on treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/37\">",
"       37",
"      </a>",
"      ]. However, when this occurs, we question the patient about possible noncompliance or poor absorption (often related to an insufficient time interval between drug intake and food ingestion).",
"     </li>",
"     <li>",
"      A third approach to monitoring takes the position that monitoring for efficacy of antiresorptive therapy is unnecessary, as only a minority of patients continue to lose bone on therapy. This approach is used infrequently by clinicians but may be applicable to patients from remote areas without access to medical facilities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients starting on therapy, we suggest a follow-up DXA of hip and spine after two years, and if BMD is stable or improved, less frequent monitoring thereafter.",
"   </p>",
"   <p>",
"    Monitoring with markers may be useful in patients who have conditions that might interfere with drug absorption or efficacy, such as small bowel resections or other types of malabsorption, or in patients who are reluctant to take anti-osteoporosis medications regularly. In such patients, we typically measure fasting urinary NTX or serum CTX before and three to six months after starting bisphosphonate or other antiresorptive therapy. If the marker has fallen significantly (by 30 to 50 percent), the patient can be reassured that the next BMD measurement will likely be stable or improved.",
"   </p>",
"   <p>",
"    In contrast, a decrease in markers of less than 30 to 50 percent may not necessarily indicate treatment failure. However, when this occurs, we question the patient about possible noncompliance or poor absorption (often related to an insufficient time interval between drug intake and food ingestion).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of biochemical markers of bone turnover for monitoring the response to osteoporosis therapy has not been addressed in most guidelines, nor are there any prospective trials to define the most optimal approach for incorporating markers into monitoring strategies.",
"   </p>",
"   <p>",
"    A consensus statement from the Belgian Bone Club addressed concerns about the limitation of using BTMs in individual patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/41\">",
"     41",
"    </a>",
"    ]. As an example, their role in monitoring bisphosphonate therapy relies upon defining the threshold reduction in BTM to attain optimal treatment effects (ie, fracture reduction). Such thresholds are not universally accepted. Until additional data are available, they suggest aiming for a reduction in BTM that returns it to the premenopausal range.",
"   </p>",
"   <p>",
"    In patients who have baseline BTMs within the premenopausal range, they suggest aiming for a decrease at least equal to the least significant change. The least significant change (LSC, defined as a change that is 2.8 times the precision error for the assay) with a 95 percent level of confidence should be established for each BTM assay. A reduction equal to or greater than the least significant change (approximately 30 percent for serum markers CTX or PINP and 50 to 60 percent for urine markers) is suggestive of bone gain and fracture prevention and may improve patient compliance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Choice of marker",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is controversy regarding which markers provide the most useful information about the subsequent risk of fractures in untreated patients and the decrease in bone loss and fracture risk in treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/28,29,37,42,43\">",
"     28,29,37,42,43",
"    </a>",
"    ]. The measurement of BTMs is complicated by large random within-patient variability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/44\">",
"     44",
"    </a>",
"    ], biologic variability (age, gender, BMI, circadian, and menstrual variation), and poor standardization of most assays. However, some clinical assays are now automated (",
"    <a class=\"graphic graphic_table graphicRef77322 \" href=\"mobipreview.htm?9/35/9789\">",
"     table 1",
"    </a>",
"    ). In addition, normative values for premenopausal women are more rigorously established. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/33/42519?source=see_link\">",
"     \"Bone physiology and biochemical markers of bone turnover\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If BTMs are used to monitor osteoporosis therapy, we suggest using BTMs that can be measured using automated technology and that have relatively small spontaneous variability, such as serum PINP, CTX, or urinary NTX (",
"    <a class=\"graphic graphic_table graphicRef77322 \" href=\"mobipreview.htm?9/35/9789\">",
"     table 1",
"    </a>",
"    ). BALP is an option in patients without liver disease. Baseline and post-treatment serum samples should be obtained under standardized conditions (fasting morning sample) and sent to the same lab. Urinary collections should also be standardized (fasting second morning void is most common).",
"   </p>",
"   <p>",
"    Each of these BTMs demonstrates different responses to treatment, such that the anticipated reduction varies for each marker. For an observed change in BTM to be clinically meaningful, it must exceed the least significant change, defined as a change that is 2.8 times the precision error for the assay. For urinary excretion of NTX, an approximately 50 percent decline is predictive of improvement in BMD and fracture risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/29,37,38\">",
"     29,37,38",
"    </a>",
"    ]. For serum CTX, PINP, and BALP a 30 percent decline is similarly predictive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/28,39,40\">",
"     28,39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Drug holiday",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is currently no consensus on how long to continue bisphosphonate therapy. However, for some women, stopping therapy after five years may be reasonable, as there appears to be a residual benefit on BMD and fractures for up to five years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H11271460#H11271460\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Alendronate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is great interest in using BTMs to determine whether patients should have a holiday from taking bisphosphonates and when such patients should resume therapy. Some clinicians follow BTMs after discontinuing bisphosphonates and restart when the BTM is more than 20 percent above the mean premenopausal level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/45\">",
"     45",
"    </a>",
"    ]. While this approach makes physiological sense, in the absence of supporting evidence, we currently do not advocate using BTMs to determine whether a drug holiday is indicated or when to restart bisphosphonate therapy after a holiday.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Dental procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some oral surgeons have proposed using a serum CTX level to assess risk and guide treatment of patients who are taking bisphosphonates and require invasive dental procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/46\">",
"     46",
"    </a>",
"    ]. They assign risk based upon CTX criteria and recommend withholding invasive dental procedures when the value is below a certain threshold. The CTX threshold was derived from 17 patients who developed osteonecrosis of the jaw (ONJ) while taking bisphosphonates. However, they did not measure CTX in a control group of unaffected bisphosphonate-treated individuals. Because bisphosphonates suppress bone resorption (which is why they are efficacious in reducing fracture), markers of bone turnover, including CTX, are reduced in patients taking bisphosphonates, and the vast majority of these patients do not get ONJ.",
"   </p>",
"   <p>",
"    It is impossible to identify a particular CTX level at which the risk of ONJ increases without also measuring CTX in large cohort of bisphosphonate-treated individuals without ONJ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44487/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Thus, until there is data supporting the ability of serum CTX to predict ONJ, we do not recommend using serum CTX to determine whether it is safe to have an invasive dental procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the use of BTMs in clinical trials has been helpful in understanding the mechanism of action of therapeutic agents, their role in the care of individual patients is not well established. Potential roles of BTMs in clinical practice include prediction of fracture risk, monitoring response to therapy, and improving compliance with therapy.",
"   </p>",
"   <p>",
"    There is no consensus on the optimal strategy for monitoring patients on antiresorptive therapy. However, we use the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients starting on therapy, we perform a DXA of the hip and spine after two years, and if BMD is stable or improved, less frequent monitoring thereafter. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Monitoring'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H31#H31\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Monitoring the response to therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with conditions that might interfere with drug absorption or efficacy or patients who are reluctant to take anti-osteoporosis medications regularly, we typically measure fasting urinary NTX, serum CTX, or serum PINP before and three to six months after starting bisphosphonates or other antiresorptive therapy. If the marker has not decreased by 50 (NTX) or 30 (CTX, PINP) percent, noncompliance or poor absorption, often related to an insufficient time interval between drug intake and food ingestion, should be considered.",
"      <br/>",
"      <br/>",
"      This approach (with markers of bone resorption) is only useful with antiresorptive therapy, not with recombinant PTH (markers would increase). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link&amp;anchor=H43#H43\">",
"       \"Parathyroid hormone therapy for osteoporosis\", section on 'Monitoring'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is no consensus on a role for BTMs in the diagnosis of osteoporosis or the selection of candidates for therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Predicting bone loss and fracture risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is currently insufficient data to support the use of BTMs for deciding when to restart bisphosphonate therapy after a drug holiday or for the assessment of risk (osteonecrosis of the jaw) in bisphosphonate-treated patients undergoing invasive dental procedures. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Drug holiday'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Dental procedures'",
"      </a>",
"      above.) However, some clinicians consider BTMs above the premenopausal range together with bone loss as indications to restart bisphosphonate therapy after a drug holiday. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H11271424#H11271424\">",
"       \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Duration of therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/1\">",
"      Bettica P, Taylor AK, Talbot J, et al. Clinical performances of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis. J Clin Endocrinol Metab 1996; 81:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/2\">",
"      Seibel MJ, Woitge H, Scheidt-Nave C, et al. Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study. J Bone Miner Res 1994; 9:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/3\">",
"      McLaren AM, Hordon LD, Bird HA, Robins SP. Urinary excretion of pyridinium crosslinks of collagen in patients with osteoporosis and the effects of bone fracture. Ann Rheum Dis 1992; 51:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/4\">",
"      Seibel MJ, Cosman F, Shen V, et al. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res 1993; 8:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/5\">",
"      Ebeling PR, Peterson JM, Riggs BL. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res 1992; 7:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/6\">",
"      Sherman SS, Tobin JD, Hollis BW, et al. Biochemical parameters associated with low bone density in healthy men and women. J Bone Miner Res 1992; 7:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/7\">",
"      Schneider DL, Barrett-Connor EL. Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density. Arch Intern Med 1997; 157:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/8\">",
"      Cummings SR, Black D. Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies. Am J Med 1995; 98:24S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/9\">",
"      Greenspan SL, Myers ER, Maitland LA, et al. Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly. JAMA 1994; 271:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/10\">",
"      Johansen JS, Riis BJ, Delmas PD, Christiansen C. Plasma BGP: an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women. Eur J Clin Invest 1988; 18:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/11\">",
"      Bonde M, Qvist P, Fledelius C, et al. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995; 80:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/12\">",
"      Chesnut CH 3rd, Bell NH, Clark GS, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997; 102:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/13\">",
"      Bauer DC, Sklarin PM, Stone KL, et al. Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J Bone Miner Res 1999; 14:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/14\">",
"      Ross PD, Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res 1998; 13:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/15\">",
"      Chaki O, Yoshikata I, Kikuchi R, et al. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women. J Bone Miner Res 2000; 15:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/16\">",
"      Ivaska KK, Lenora J, Gerdhem P, et al. Serial assessment of serum bone metabolism markers identifies women with the highest rate of bone loss and osteoporosis risk. J Clin Endocrinol Metab 2008; 93:2622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/17\">",
"      Bauer DC, Garnero P, Harrison SL, et al. Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study. J Bone Miner Res 2009; 24:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/18\">",
"      van Daele PL, Seibel MJ, Burger H, et al. Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study. BMJ 1996; 312:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/19\">",
"      Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996; 11:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/20\">",
"      Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000; 15:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/21\">",
"      Gerdhem P, Ivaska KK, Alatalo SL, et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 2004; 19:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/22\">",
"      Delmas PD, Licata AA, Reginster JY, et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone 2006; 39:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/23\">",
"      Sornay-Rendu E, Munoz F, Garnero P, et al. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 2005; 20:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/24\">",
"      Meier C, Nguyen TV, Center JR, et al. Bone resorption and osteoporotic fractures in elderly men: the dubbo osteoporosis epidemiology study. J Bone Miner Res 2005; 20:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/25\">",
"      Ivaska KK, Gerdhem P, V&auml;&auml;n&auml;nen HK, et al. Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9 years. J Bone Miner Res 2010; 25:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/26\">",
"      Johnell O, Kanis JA, Black DM, et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res 2004; 19:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/27\">",
"      Melton LJ 3rd, Crowson CS, O'Fallon WM, et al. Relative contributions of bone density, bone turnover, and clinical risk factors to long-term fracture prediction. J Bone Miner Res 2003; 18:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/28\">",
"      Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004; 19:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/29\">",
"      Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003; 18:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/30\">",
"      Bjarnason NH, Sarkar S, Duong T, et al. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 2001; 12:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/31\">",
"      Sarkar S, Reginster JY, Crans GG, et al. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 2004; 19:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/32\">",
"      Eastell R, Hannon RA, Garnero P, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res 2007; 22:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/33\">",
"      Reginster JY, Sarkar S, Zegels B, et al. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 2004; 34:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/34\">",
"      Dobnig H, Sipos A, Jiang Y, et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 2005; 90:3970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/35\">",
"      Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004; 89:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/36\">",
"      Delmas PD, Vrijens B, Eastell R, et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2007; 92:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/37\">",
"      Ravn P, Hosking D, Thompson D, et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 1999; 84:2363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/38\">",
"      Rosen HN, Moses AC, Garber J, et al. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif Tissue Int 1998; 63:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/39\">",
"      Rosen HN, Moses AC, Garber J, et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000; 66:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/40\">",
"      Christgau S, Rosenquist C, Alexandersen P, et al. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 1998; 44:2290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/41\">",
"      Bergmann P, Body JJ, Boonen S, et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract 2009; 63:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/42\">",
"      Seibel MJ, Naganathan V, Barton I, Grauer A. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 2004; 19:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/43\">",
"      Rosen CJ, Chesnut CH 3rd, Mallinak NJ. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 1997; 82:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/44\">",
"      Bell KJ, Hayen A, Irwig L, et al. The potential value of monitoring bone turnover markers among women on alendronate. J Bone Miner Res 2012; 27:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/45\">",
"      Singer FR, Eyre DR. Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med 2008; 75:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/46\">",
"      Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65:2397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/47\">",
"      American Society for Bone and Mineral Research Task Force on Osteonecrosis of the Jaw, Khosla S, Burr D, et al. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2008; 66:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44487/abstract/48\">",
"      Baim S, Miller PD. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 2009; 24:561.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2041 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-1.234.2.38-DECD7EA589-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_28_44487=[""].join("\n");
var outline_f43_28_44487=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREDICTING BONE LOSS AND FRACTURE RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BTMs AND OSTEOPOROSIS THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Efficacy of osteoporosis therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Improving compliance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Choice of marker",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Drug holiday",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Dental procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2041\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2041|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/56/16271\" title=\"figure 1\">",
"      NTX excretion bone density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/27/20925\" title=\"figure 2\">",
"      DPD excretion in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/42/37550\" title=\"figure 3\">",
"      Bone markers and bone loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/47/39677\" title=\"figure 4\">",
"      Bone markers risk hip fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2041|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/35/9789\" title=\"table 1\">",
"      BTM assays",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/33/42519?source=related_link\">",
"      Bone physiology and biochemical markers of bone turnover",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2234?source=related_link\">",
"      Investigational biologic markers in the diagnosis and assessment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=related_link\">",
"      Parathyroid hormone therapy for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=related_link\">",
"      Pathogenesis of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_28_44488="Renal disease associated with hepatitis B virus infection";
var content_f43_28_44488=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal disease associated with hepatitis B virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/28/44488/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/28/44488/contributors\">",
"     Tak-Mao Chan, MD, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/28/44488/contributors\">",
"     Anna SF Lok, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/28/44488/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/28/44488/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/28/44488/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/28/44488/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/28/44488/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/28/44488/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with hepatitis B virus (HBV) may be associated with a variety of renal diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The three most common types of renal disease resulting from HBV infection are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Membranous glomerulonephritis",
"     </li>",
"     <li>",
"      Membranoproliferative glomerulonephritis (MPGN)",
"     </li>",
"     <li>",
"      Polyarteritis nodosa (PAN)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, HBV infection has been associated with mesangial proliferative glomerulonephritis, IgA nephropathy, and amyloidosis.",
"   </p>",
"   <p>",
"    This topic provides an overview of types of renal disease associated with HBV infection, as well as the diagnosis and management of such patients. When necessary, the reader is directed to more detailed discussions on the clinical manifestations and diagnosis of specific renal diseases and the serologic diagnosis of hepatitis B. Full discussions of hepatitis B infection in patients receiving hemodialysis and patients with a kidney transplant are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/5/40024?source=see_link\">",
"     \"Hepatitis B virus and dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/37/1625?source=see_link\">",
"     \"Hepatitis B virus infection in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1340257\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1340265\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal disease associated with hepatitis B virus (HBV) infection most commonly occurs in endemic areas, particularly when infection occurs during infancy and early childhood, which increases the probability of becoming a chronic carrier [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/3\">",
"     3",
"    </a>",
"    ]. In comparison, the frequency of HBV-related renal disease is low in the United States and western Europe due to the lower prevalence of chronic HBV infection in general and a lower likelihood of childhood infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4602?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/41/31386?source=see_link\">",
"     \"Overview of hepatitis B virus infection in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The widespread use of hepatitis B vaccination has decreased the incidence of HBV-related renal diseases, providing evidence of the probable pathogenetic role of HBV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1340332\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some affected patients have a history of active hepatitis, a large proportion of patients have only mild to moderate elevations in serum aminotransferases. These patients are generally positive for hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc), and, in patients with membranous nephropathy, hepatitis B e antigen (HBeAg). The relationship among HBV variants (eg, precore and core promoter) that are negative for HBeAg (despite active viral replication by DNA testing) and renal disease has not been well described. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6250?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical significance and molecular characteristics of common hepatitis B virus variants\", section on 'Precore and core promoter variants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenetic role of HBV infection has been documented primarily by the demonstration of hepatitis B antigen-antibody complexes in the renal lesions via immunofluorescence microscopy, including deposition of HBeAg in membranous nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/1,6,7\">",
"     1,6,7",
"    </a>",
"    ]. HBV DNA and HBV RNA have been localized to glomerular and tubular cells in affected patients; however, the role of these viral nucleic acids in the development of renal injury remains to be confirmed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF RENAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The renal diseases most commonly associated with hepatitis B virus (HBV) infection include membranous nephropathy, membranoproliferative glomerulonephritis (MPGN), and polyarteritis nodosa (PAN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/1,2,6\">",
"     1,2,6",
"    </a>",
"    ]. The clinical manifestations of these three diseases are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link\">",
"     \"Causes and diagnosis of membranous nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43833?source=see_link\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Membranous nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBV-associated secondary membranous nephropathy, as with other forms of membranous nephropathy, usually presents with proteinuria, which can be in the nephrotic range. The histologic presence of mesangial or subendothelial immune deposits, in addition to the typical subepithelial localization, may be a clue to suggest secondary rather than primary membranous nephropathy.",
"   </p>",
"   <p>",
"    It has been proposed that the deposition of hepatitis B e antigen (HBeAg) and anti-HBe immune complexes in the subepithelial region of the glomerular basement membrane is pivotal to disease pathogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/1,6,7,10\">",
"     1,6,7,10",
"    </a>",
"    ]. HBV-associated membranous nephropathy is more common in children and resolves spontaneously in many cases, usually in association with seroconversion from HBeAg to anti-HBe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast, spontaneous resolution is relatively uncommon in adults, and some patients show progressive renal deterioration over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/2,7,11\">",
"     2,7,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link&amp;anchor=H10#H10\">",
"     \"Causes and diagnosis of membranous nephropathy\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Membranoproliferative glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBV-associated MPGN, as with other forms of MPGN, presents with hematuria (often with dysmorphic red blood cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    red blood cell casts) and variable degrees of proteinuria, reduced glomerular filtration rate, and hypertension. The histologic deposition of circulating antigen-antibody complexes in the mesangium and subendothelial space characterizes the MPGN associated with HBV. Both hepatitis B surface antigen (HBsAg) and HBeAg deposition have been implicated in this disorder, although their exact role remains uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43833?source=see_link&amp;anchor=H92986245#H92986245\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\", section on 'MPGN type I'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compared with hepatitis C infection, HBV infection is a rare cause of mixed cryoglobulinemia, which can be associated with MPGN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37353?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Polyarteritis nodosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;PAN is a necrotizing vasculitis affecting small- and medium-sized blood vessels that produces multi-organ involvement; renal involvement leads to variable degrees of reduced glomerular filtration rate and hypertension. The clinical features of HBV-associated PAN are similar to idiopathic PAN. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HBV-associated PAN typically occurs within four months after the onset of HBV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/14\">",
"     14",
"    </a>",
"    ]. The presence of HBV-associated disease is suggested by the findings of HBsAg, HBeAg, and HBV DNA (an indicator of viral replication) in the serum. The deposition of circulating antigen-antibody immune complexes in the vessel wall triggers downstream inflammatory processes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A kidney biopsy is required to confirm the presence of an underlying glomerular process, although a different tissue site may be biopsied to confirm polyarteritis nodosa (PAN). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\", section on 'Tissue biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Confirming the etiologic role of hepatitis B virus (HBV) in any of these disorders may, at times, be difficult since the detection of viral antigen deposition in the kidney requires techniques that may not be available in the routine clinical setting. In addition, the presence of viral antigens in the renal tissue may be coincidental rather than indicative of a causal relationship [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/6\">",
"     6",
"    </a>",
"    ]. However, a presumptive diagnosis may be made in patients whose biopsy findings are consistent with an HBV-associated renal disease and when the patient is a child from an HBV-endemic area or an adult whose serologic tests show circulating hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p>",
"    In such patients, we also recommend HBV DNA testing to confirm active viral replication. Concurrent infection with hepatitis C virus should be investigated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnosing HBV-associated renal disease is important because therapy with corticosteroids and cytotoxic agents, which are common therapies for idiopathic forms of the above disorders, may not be beneficial in patients with HBV-associated renal disease and may lead to reactivation of HBV replication, hepatitis flares, and liver failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of hepatitis B virus (HBV) infection-associated renal diseases consists of antiviral therapy in most patients. This recommendation is consistent with treatment guidelines produced by Kidney Disease: Improving Global Outcomes (KDIGO) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/15\">",
"     15",
"    </a>",
"    ]. In severe cases of polyarteritis nodosa (PAN), a short course of immunosuppression and plasmapheresis may be considered.",
"   </p>",
"   <p>",
"    The limited data on the treatment of HBV-associated renal diseases are based upon small case series and uncontrolled observations. There are no randomized trials. In addition, the treatment of children and adults with HBV-associated renal disease differs because the natural history of such diseases also differs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1340634\">",
"    <span class=\"h2\">",
"     Antiviral therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1340671\">",
"    <span class=\"h3\">",
"     Indications for antiviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with HBV-associated renal disease and both seropositivity for hepatitis B e antigen (HBeAg) and evidence of active viral replication (the HBV DNA test is positive), we recommend antiviral therapy. This recommendation is based upon observational data and uncontrolled interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/2,7,11,16-24\">",
"     2,7,11,16-24",
"    </a>",
"    ]. Both interferon alfa and nucleoside analogs have been used. The following examples illustrate the quality of the data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective report from the National Institutes of Health (NIH) evaluated 15 adults (10 with membranous nephropathy, 4 with membranoproliferative glomerulonephritis (MPGN), and 1 in whom renal biopsy was not available) who were treated with 5 million units of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29576?source=see_link\">",
"       interferon alfa-2b",
"      </a>",
"      subcutaneously daily for 16 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/17\">",
"       17",
"      </a>",
"      ]. Eight responded with seroconversion of HBeAg to anti-HBe antibodies and a reduction of HBV DNA to undetectable levels by hybridization assay. In seven patients, this was accompanied by gradual disappearance of proteinuria. Responders had lower baseline HBeAg and HBV DNA levels than nonresponders. In responders, remission persisted for a prolonged period after therapy was discontinued. Patients with membranoproliferative disease appeared less responsive to treatment. The dose of interferon alfa-2b was lowered in seven patients due to side effects (fatigue or anemia). In two patients, therapy was discontinued (one patient had intractable fatigue and the other had a seizure).",
"      <br/>",
"      <br/>",
"      Other studies that examined interferon alfa for HBV-associated renal disease reported sustained seroconversion of HBeAg to anti-HBe in 38 to 80 percent of patients and remission of proteinuria in 25 to 100 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/11,18-20\">",
"       11,18-20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ten adult patients with HBV-associated membranous nephropathy were treated with the nucleoside analog,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      , and compared with 12 historical controls who had the same diagnosis but were not treated with lamivudine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/25\">",
"       25",
"      </a>",
"      ]. Treatment with lamivudine was associated with disappearance of HBV DNA and reduction of proteinuria. Six of 10 treated and 3 of 12 untreated patients had remission of proteinuria to &lt;0.3",
"      <span class=\"nowrap\">",
"       g/24",
"      </span>",
"      hours. There are anecdotal data on the efficacy of lamivudine in HBV-associated MPGN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1340693\">",
"    <span class=\"h3\">",
"     Choice of therapy, duration, and therapeutic goal",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two options for antiviral therapy: interferon alfa (usually pegylated interferon alfa) and",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    analogs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef58520 \" href=\"mobipreview.htm?26/32/27149\">",
"     table 1",
"    </a>",
"    ). Interferon has an immunomodulatory effect in addition to its ability to suppress HBV replication.",
"    <span class=\"nowrap\">",
"     Nucleoside/nucleotide",
"    </span>",
"    analogs suppress viral replication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the management of hepatitis B and case examples\", section on 'Choosing among the available options'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19584908\">",
"    <span class=\"h4\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, we prefer interferon alfa in children and young adults and",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    analogs in older adults.",
"   </p>",
"   <p>",
"    Interferon is less well-tolerated but is more likely to induce a sustained remission. Thus, it should be considered in children and young adults who can better tolerate interferon or who do not want to be on prolonged",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    therapy. In addition, the newer",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    analogs that have a lower risk of drug resistance, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , have not been approved for use in children. We prefer pegylated interferon, which has superseded standard interferon in the treatment of chronic hepatitis B, although it has not been studied in patients with HBV-associated renal disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the management of hepatitis B and case examples\", section on 'Who should be treated and how'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14281?source=see_link\">",
"     \"Standard and pegylated interferon for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We prefer",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    analogs rather than interferon in older adults. In addition, interferon is",
"    <strong>",
"     not",
"    </strong>",
"    recommended in patients with cirrhosis (",
"    <a class=\"graphic graphic_table graphicRef58520 \" href=\"mobipreview.htm?26/32/27149\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the management of hepatitis B and case examples\", section on 'Who should be treated and how'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When a",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    analog is used,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    is preferred in view of its antiviral efficacy and low propensity for drug resistance. The dose of",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    analog needs to be reduced in patients with impaired renal function (",
"    <a class=\"graphic graphic_table graphicRef71024 \" href=\"mobipreview.htm?15/56/16269\">",
"     table 2",
"    </a>",
"    ). In view of the nephrotoxicity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    and, to a lesser extent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , these two drugs are",
"    <strong>",
"     not",
"    </strong>",
"    preferred unless required in patients who have developed resistance to other agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the management of hepatitis B and case examples\", section on 'Who should be treated and how'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11752?source=see_link\">",
"     \"Entecavir in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6538?source=see_link\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If initial therapy with interferon is ineffective or not well tolerated, we will switch to a",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    analog. Conversely, if initial therapy with a",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    analog fails, we will consider a course of interferon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19585026\">",
"    <span class=\"h4\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of antiviral treatment is unclear. Many patients treated with",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    analogs, except for those who achieve rapid HBeAg conversion to anti-HBe, will require prolonged treatment.",
"   </p>",
"   <p>",
"    The duration of therapy depends upon the type of drug used, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interferon is given for a finite duration. When using interferon alfa, we treat for 16 weeks if the patient is HBeAg-positive and 48 weeks if the patient is HBeAg-negative. Pegylated interferon is given for 48 weeks in both HBeAg-positive and HBeAg-negative patients (",
"      <a class=\"graphic graphic_table graphicRef58520 \" href=\"mobipreview.htm?26/32/27149\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If a",
"      <span class=\"nowrap\">",
"       nucleoside/nucleotide",
"      </span>",
"      analog is used, treatment is continued for at least 12 months after seroconversion of HBeAg (to anti-HBe). Patients who are HBeAg-negative at the start of treatment often require lifelong therapy. In such patients, treatment discontinuation may be attempted in the small fraction of patients who meet the following criteria: the hepatitis B surface antigen (HBsAg) becomes negative after initiation of treatment, and cirrhosis is not present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19585139\">",
"    <span class=\"h4\">",
"     Therapeutic goal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of antiviral therapy depends upon the presence or absence of HBeAg at baseline. HBeAg is considered to be a marker of HBV replication and infectivity. HBeAg seroconversion (disappearance of HBeAg and appearance of anti-HBe antibodies) is usually associated with a decrease in HBV DNA and remission. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42279?source=see_link&amp;anchor=H6#H6\">",
"     \"Serologic diagnosis of hepatitis B virus infection\", section on 'Hepatitis B e antigen and antibody'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=see_link&amp;anchor=H34#H34\">",
"     \"Overview of the management of hepatitis B and case examples\", section on 'Duration and treatment endpoints'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who are initially HBeAg seropositive, the therapeutic goal is HBeAg seroconversion to anti-HBe.",
"     </li>",
"     <li>",
"      In patients who are initially HBeAg-negative, the therapeutic goal is suppression of viremia, which requires monitoring of HBV DNA levels to ensure that therapy is effective. In patients treated with a",
"      <span class=\"nowrap\">",
"       nucleoside/nucleotide",
"      </span>",
"      analog, lifelong therapy may be required. As noted above, however, if the HBsAg becomes negative in a patient without cirrhosis, discontinuation of the",
"      <span class=\"nowrap\">",
"       nucleoside/nucleotide",
"      </span>",
"      analog can be attempted. &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1341133\">",
"    <span class=\"h2\">",
"     Limited role for immunosuppression and plasmapheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;We advise",
"    <strong>",
"     against",
"    </strong>",
"    using immunosuppressive therapy or plasmapheresis in most patients with HBV-associated renal disease. However, immunosuppression (with or without plasmapheresis) in combination with antiviral therapy should be considered in patients who have:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rapidly progressive glomerulonephritis (RPGN)",
"     </li>",
"     <li>",
"      PAN with severe manifestations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Except for these two indications, data from observational studies suggest that immunosuppressive therapy with corticosteroids or cytotoxic agents and plasmapheresis are of little benefit and are potentially harmful. This is particularly true among children with membranous nephropathy in whom spontaneous recovery over 6 to 24 months is common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/1,2,10\">",
"     1,2,10",
"    </a>",
"    ]. Antiviral monotherapy may also be sufficient to treat HBV-associated PAN in patients who do not have severe or life-threatening disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. In addition, immunosuppressive therapy can trigger an increase in viral replication and possibly lead to exacerbation of chronic hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19585728\">",
"    <span class=\"h3\">",
"     RPGN",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with rapidly progressive (crescentic) glomerulonephritis due to HBV infection, we suggest both antiviral medication (preferably a",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    analog) and a short course of glucocorticoids with or without an immunosuppressant, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (the latter must be accompanied by antiviral therapy since it may lead to increased viral replication). The glucocorticoid regimen consists of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for three days, followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , 0.7 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, tapered over four to six months. Antiviral therapy and monitoring of HBV DNA levels are continued for at least six months after cessation of immunosuppressive therapy or until the therapeutic goal is achieved. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H19585139\">",
"     'Therapeutic goal'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19585735\">",
"    <span class=\"h3\">",
"     PAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppression and plasma exchange are part of many published treatment protocols for HBV-associated PAN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/14,22-24,29-33\">",
"     14,22-24,29-33",
"    </a>",
"    ]. Glucocorticoids suppress the inflammatory component of the vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/10,14\">",
"     10,14",
"    </a>",
"    ] and may improve survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/34\">",
"     34",
"    </a>",
"    ], although they can enhance viral replication and lead to exacerbation of chronic hepatitis. Plasmapheresis removes circulating immune complexes, which may be beneficial in patients with severe disease manifestations.",
"   </p>",
"   <p>",
"    In patients with mild PAN, we treat with antiviral therapy alone. However, in patients with PAN and severe manifestations (defined by the presence of ulcerative or gangrenous lesions of the extremities, acute kidney injury, polyneuropathy, central nervous system involvement, mesenteric arteritis, or myocardial ischemia), we treat with both glucocorticoids and plasmapheresis in addition to antiviral therapy (preferably a",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    analog), although the data supporting the use of plasma exchange are weak. The glucocorticoid and plasmapheresis regimens that we use are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      0.7 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, tapered over four to six months",
"     </li>",
"     <li>",
"      Plasma exchange, 2.5 to 4.0 liters per session for a total of 6 to 10 sessions, daily or on alternate days over two to three weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with RPGN, antiviral therapy and monitoring of HBV DNA levels are continued for at least six months after cessation of immunosuppressive therapy or until the therapeutic goal is achieved. In a patient treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , antiviral therapy should be continued for 12 months after the rituximab is discontinued. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H19585139\">",
"     'Therapeutic goal'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Treatment of HBV-associated PAN with immunosuppression and plasmapheresis should be combined with antiviral therapy. The benefits of combination therapy were shown in a retrospective series of 80 patients with HBV-associated PAN who were treated with an antiviral agent (vidarabine, interferon-alfa or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , depending upon the era), a two-week course of corticosteroids, and an intensive schedule of plasma exchange [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/35\">",
"     35",
"    </a>",
"    ]. Their course and outcomes were compared with 35 historic controls (before the antiviral era) treated with corticosteroids with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , with most receiving plasma exchange. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remission was attained by 81 percent of all patients; patients who did not achieve remission died within a mean of 178 days. Overall five-year survival was 73 percent.",
"     </li>",
"     <li>",
"      At a median follow-up of 237 months, combination therapy with antivirals, immunosuppression, and plasmapheresis was associated with lower rates of relapse (4 versus 14 percent) and death (30 versus 49 percent), although the differences did not reach statistical significance.",
"     </li>",
"     <li>",
"      Combination therapy was associated with a significantly higher rate of HBeAg seroconversion to anti-HBe (49 versus 15 percent), which predicted a sustained remission. Seroconversion rates were similar for interferon and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (both over 60 percent) but lower for vidarabine (41 percent), which is no longer used due to neurotoxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    to glucocorticoids and plasma exchange does not appear to improve long-term outcomes in HBV-associated PAN, although initial disease control may be better [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/29,35\">",
"     29,35",
"    </a>",
"    ]. There are no data on the role of other immunosuppressive agents, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , in the treatment of HBV-associated PAN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44488/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Vidarabine is no longer used for hepatitis B because of neurologic side effects and low antiviral efficacy. Although data on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    in HBV-associated PAN are lacking, these newer",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    analogs are preferred to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    because of low risk of drug resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19585245\">",
"    <span class=\"h2\">",
"     Concomitant HCV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with concomitant hepatitis C infection is complex. The choice of therapy depends upon the state of viral replication of the two viruses. HBV DNA and HCV RNA levels should be measured to determine which virus is dominant and thus most likely responsible for the underlying renal pathology. Interferon may be a logical therapeutic choice since it is active against both viruses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37353?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/26/30122?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\", section on 'Coinfection with HCV or HDV'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal disease associated with hepatitis B virus (HBV) infection most commonly occurs in endemic areas, particularly when infection occurs during infancy and early childhood, which increases the probability of becoming a chronic carrier. (See",
"      <a class=\"local\" href=\"#H1340265\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenetic role of HBV infection has been documented primarily by the demonstration of hepatitis B antigen-antibody complexes in the renal lesions via immunofluorescence microscopy. (See",
"      <a class=\"local\" href=\"#H1340332\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The renal diseases most commonly associated with HBV infection include (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of renal disease'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Membranous nephropathy, which usually presents with proteinuria that can be in the nephrotic range (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Membranous nephropathy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Membranoproliferative glomerulonephritis (MPGN), which presents with hematuria (often with dysmorphic red blood cells",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      red blood cell casts) and variable degrees of proteinuria, reduced glomerular filtration rate, and hypertension (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Membranoproliferative glomerulonephritis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Polyarteritis nodosa (PAN), which is a necrotizing vasculitis affecting small- and medium-sized blood vessels that produces multi-organ involvement; renal involvement leads to variable degrees of reduced glomerular filtration rate and hypertension (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Polyarteritis nodosa'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A kidney biopsy is required to confirm the presence of an underlying glomerular process, although a different tissue site may be biopsied to confirm PAN. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Confirming the etiologic role of HBV in any of these disorders may, at times, be difficult. However, a presumptive diagnosis may be made in patients whose biopsy findings are consistent with an HBV-associated renal disease and when the patient is a child from an HBV-endemic area or an adult whose serologic tests show circulating hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg). In such patients, we also recommend HBV DNA testing to confirm active viral replication. Concurrent infection with hepatitis C virus should be investigated. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with HBV-associated renal disease and both seropositivity for HBeAg and evidence of active viral replication (the HBV DNA test is positive), we recommend antiviral therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1340671\">",
"       'Indications for antiviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two options for antiviral therapy: interferon alfa (usually pegylated interferon alfa) and",
"      <span class=\"nowrap\">",
"       nucleoside/nucleotide",
"      </span>",
"      analogs, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef58520 \" href=\"mobipreview.htm?26/32/27149\">",
"       table 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H19584908\">",
"       'Choice of therapy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In children and young adults, we suggest initial therapy with interferon alfa (usually pegylated interferon alfa) rather than",
"      <span class=\"nowrap\">",
"       nucleoside/nucleotide",
"      </span>",
"      analogs (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Interferon is less well-tolerated but is more likely to induce a sustained remission.",
"     </li>",
"     <li>",
"      In older adults and in patients with cirrhosis, we suggest initial therapy with",
"      <span class=\"nowrap\">",
"       nucleoside/nucleotide",
"      </span>",
"      analogs rather than interferon (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The dose of",
"      <span class=\"nowrap\">",
"       nucleoside/nucleotide",
"      </span>",
"      analog needs to be reduced in patients with impaired renal function (",
"      <a class=\"graphic graphic_table graphicRef71024 \" href=\"mobipreview.htm?15/56/16269\">",
"       table 2",
"      </a>",
"      ). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The duration of therapy depends upon the type of drug used, as follows (see",
"      <a class=\"local\" href=\"#H19585026\">",
"       'Duration of therapy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Interferon is given for a finite duration (",
"      <a class=\"graphic graphic_table graphicRef58520 \" href=\"mobipreview.htm?26/32/27149\">",
"       table 1",
"      </a>",
"      ). When using pegylated interferon alfa, we treat for 48 weeks. If standard interferon alfa is used, it is given for 16 weeks if the patient is HBeAg-positive and 48 weeks if the patient is HBeAg-negative. Pegylated interferon is given for 48 weeks in both HBeAg-positive and HBeAg-negative patients (",
"      <a class=\"graphic graphic_table graphicRef58520 \" href=\"mobipreview.htm?26/32/27149\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If a",
"      <span class=\"nowrap\">",
"       nucleoside/nucleotide",
"      </span>",
"      analog is used, treatment is continued for at least 12 months after seroconversion of HBeAg (to anti-HBe). Patients who are HBeAg-negative at the start of treatment often require lifelong therapy. In such patients, treatment discontinuation may be attempted in the small fraction of patients who meet the following criteria: the HBsAg becomes negative after initiation of treatment, and cirrhosis is not present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal of antiviral therapy depends upon the presence or absence of HBeAg at baseline (see",
"      <a class=\"local\" href=\"#H19585139\">",
"       'Therapeutic goal'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients who are initially HBeAg seropositive, the therapeutic goal is HBeAg seroconversion to anti-HBe.",
"     </li>",
"     <li>",
"      In patients who are initially HBeAg-negative, the therapeutic goal is suppression of viremia, which requires monitoring of HBV DNA levels to ensure that therapy is effective. In patients treated with a",
"      <span class=\"nowrap\">",
"       nucleoside/nucleotide",
"      </span>",
"      analog, lifelong therapy may be required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with HBV-associated renal disease who do",
"      <strong>",
"       not",
"      </strong>",
"      have rapidly progressive glomerulonephritis (RPGN) or severe PAN, we suggest not giving immunosuppression (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Except for these two indications, immunosuppressive therapy with corticosteroids or cytotoxic agents and plasmapheresis are of little benefit and are potentially harmful. (See",
"      <a class=\"local\" href=\"#H1341133\">",
"       'Limited role for immunosuppression and plasmapheresis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with RPGN due to HBV infection, we suggest immunosuppression in addition to antiviral medication (preferably a",
"      <span class=\"nowrap\">",
"       nucleoside/nucleotide",
"      </span>",
"      analog) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In such cases, we usually treat with a short course of glucocorticoids with or without an immunosuppressant, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H19585728\">",
"       'RPGN'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with PAN and severe manifestations (defined by the presence of ulcerative or gangrenous lesions of the extremities, acute kidney injury, polyneuropathy, central nervous system involvement, mesenteric arteritis, or myocardial ischemia), we suggest immunosuppression in addition to antiviral medication (preferably a",
"      <span class=\"nowrap\">",
"       nucleoside/nucleotide",
"      </span>",
"      analog) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In such cases, we usually treat with both glucocorticoids and plasmapheresis. (See",
"      <a class=\"local\" href=\"#H19585735\">",
"       'PAN'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/1\">",
"      Johnson RJ, Couser WG. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int 1990; 37:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/2\">",
"      Lai KN, Lai FM. Clinical features and the natural course of hepatitis B virus-related glomerulopathy in adults. Kidney Int Suppl 1991; 35:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/3\">",
"      Levy M, Chen N. Worldwide perspective of hepatitis B-associated glomerulonephritis in the 80s. Kidney Int Suppl 1991; 35:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/4\">",
"      Xu H, Sun L, Zhou LJ, et al. The effect of hepatitis B vaccination on the incidence of childhood HBV-associated nephritis. Pediatr Nephrol 2003; 18:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/5\">",
"      Liao MT, Chang MH, Lin FG, et al. Universal hepatitis B vaccination reduces childhood hepatitis B virus-associated membranous nephropathy. Pediatrics 2011; 128:e600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/6\">",
"      Takekoshi Y, Tochimaru H, Nagata Y, Itami N. Immunopathogenetic mechanisms of hepatitis B virus-related glomerulopathy. Kidney Int Suppl 1991; 35:S34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/7\">",
"      Lai KN, Li PK, Lui SF, et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 1991; 324:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/8\">",
"      Lai KN, Ho RT, Tam JS, Lai FM. Detection of hepatitis B virus DNA and RNA in kidneys of HBV related glomerulonephritis. Kidney Int 1996; 50:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/9\">",
"      Hong L, Zhang J, Min J, et al. A role for MHBst167/HBx in hepatitis B virus-induced renal tubular cell apoptosis. Nephrol Dial Transplant 2010; 25:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/10\">",
"      Guillevin L, Lhote F. Treatment of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum 1998; 41:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/11\">",
"      Lin CY. Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int 1995; 47:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/12\">",
"      Perez GO, Pardo V, Fletcher M. Renal involvement in essential mixed cryoglobulinemia. Am J Kidney Dis 1987; 10:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/13\">",
"      Enr&iacute;quez R, Sirvent AE, Andrada E, et al. Cryoglobulinemic glomerulonephritis in chronic hepatitis B infection. Ren Fail 2010; 32:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/14\">",
"      Guillevin L, Lhote F, Cohen P, et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) 1995; 74:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/15\">",
"      KDIGO. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012; 2:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/16\">",
"      Lisker-Melman M, Webb D, Di Bisceglie AM, et al. Glomerulonephritis caused by chronic hepatitis B virus infection: treatment with recombinant human alpha-interferon. Ann Intern Med 1989; 111:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/17\">",
"      Conjeevaram HS, Hoofnagle JH, Austin HA, et al. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. Gastroenterology 1995; 109:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/18\">",
"      Chung DR, Yang WS, Kim SB, et al. Treatment of hepatitis B virus associated glomerulonephritis with recombinant human alpha interferon. Am J Nephrol 1997; 17:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/19\">",
"      Bhimma R, Coovadia HM, Kramvis A, et al. Treatment of hepatitis B virus-associated nephropathy in black children. Pediatr Nephrol 2002; 17:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/20\">",
"      Fabrizi F, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis. Aliment Pharmacol Ther 2006; 24:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/21\">",
"      Wen YK, Chen ML. Remission of hepatitis B virus-associated membranoproliferative glomerulonephritis in a cirrhotic patient after lamivudine therapy. Clin Nephrol 2006; 65:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/22\">",
"      Kruger M, B&ouml;ker KH, Zeidler H, Manns MP. Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b. J Hepatol 1997; 26:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/23\">",
"      Av��ar E, Sava�� B, T&ouml;z&uuml;n N, et al. Successful treatment of polyarteritis nodosa related to hepatitis B virus with interferon alpha as first-line therapy. J Hepatol 1998; 28:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/24\">",
"      Simsek H, Telatar H. Successful treatment of hepatitis B virus-associated polyarteritis nodosa by interferon alpha alone. J Clin Gastroenterol 1995; 20:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/25\">",
"      Tang S, Lai FM, Lui YH, et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 2005; 68:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/26\">",
"      Lin CY, Lo SC. Treatment of hepatitis B virus-associated membranous nephropathy with adenine arabinoside and thymic extract. Kidney Int 1991; 39:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/27\">",
"      Lai KN, Tam JS, Lin HJ, Lai FM. The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia. Nephron 1990; 54:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/28\">",
"      Sayarlioglu H, Erkoc R, Dogan E, et al. Mycophenolate mofetil use in hepatitis B associated-membranous and membranoproliferative glomerulonephritis induces viral replication. Ann Pharmacother 2005; 39:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/29\">",
"      Guillevin L, Pagnoux C. Indications of plasma exchanges for systemic vasculitides. Ther Apher Dial 2003; 7:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/30\">",
"      Wicki J, Olivieri J, Pizzolato G, et al. Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon alpha. Rheumatology (Oxford) 1999; 38:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/31\">",
"      Guillevin L, Lhote F, Sauvaget F, et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 1994; 53:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/32\">",
"      Guillevin L, Mahr A, Cohen P, et al. Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum 2004; 51:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/33\">",
"      Janssen HL, van Zonneveld M, van Nunen AB, et al. Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome. Eur J Gastroenterol Hepatol 2004; 16:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/34\">",
"      Leib ES, Restivo C, Paulus HE. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med 1979; 67:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/35\">",
"      Guillevin L, Mahr A, Callard P, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/36\">",
"      Fernanda F, Serena C, Giustina R, et al. Mycophenolate mofetil treatment in two children with severe polyarteritis nodosa refractory to immunosuppressant drugs. Rheumatol Int 2012; 32:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44488/abstract/37\">",
"      N&eacute;el A, Masseau A, Hervier B, et al. Life-threatening hepatitis C virus-associated polyarteritis nodosa successfully treated by rituximab. J Clin Rheumatol 2011; 17:439.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3119 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-AD1D6AEAC5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_28_44488=[""].join("\n");
var outline_f43_28_44488=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1340257\">",
"      EPIDEMIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1340265\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1340332\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF RENAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1340634\">",
"      Antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1340671\">",
"      - Indications for antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1340693\">",
"      - Choice of therapy, duration, and therapeutic goal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19584908\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19585026\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19585139\">",
"      Therapeutic goal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1341133\">",
"      Limited role for immunosuppression and plasmapheresis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19585728\">",
"      - RPGN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19585735\">",
"      - PAN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19585245\">",
"      Concomitant HCV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3119\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3119|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/32/27149\" title=\"table 1\">",
"      AASLD Rx chronic HBV recs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/56/16269\" title=\"table 2\">",
"      Chron HBV dosage adjustment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=related_link\">",
"      Causes and diagnosis of membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=related_link\">",
"      Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/26/30122?source=related_link\">",
"      Clinical manifestations and natural history of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43833?source=related_link\">",
"      Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6250?source=related_link\">",
"      Clinical significance and molecular characteristics of common hepatitis B virus variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11752?source=related_link\">",
"      Entecavir in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/5/40024?source=related_link\">",
"      Hepatitis B virus and dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/37/1625?source=related_link\">",
"      Hepatitis B virus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6538?source=related_link\">",
"      Lamivudine monotherapy for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/41/31386?source=related_link\">",
"      Overview of hepatitis B virus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37353?source=related_link\">",
"      Renal disease associated with hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14281?source=related_link\">",
"      Standard and pegylated interferon for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_28_44489="Induction therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults";
var content_f43_28_44489=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Induction therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/28/44489/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/28/44489/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/28/44489/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/28/44489/contributors\">",
"     Bob Lowenberg, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/28/44489/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/28/44489/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/28/44489/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H60603478\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute lymphoblastic leukemia (ALL) refers to a group of hematopoietic neoplasms involving cells committed to the lymphoid lineage. Philadelphia chromosome positive ALL (Ph+ ALL) is a biologically and clinically distinct variant of ALL classified as ALL with t(9;22)(q34;q11.2);BCR-ABL1 in the WHO classification system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/1\">",
"     1",
"    </a>",
"    ]. Ph+ ALL accounts for approximately 20 to 30 percent of ALL in adults and 2 to 3 percent of ALL in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When treated with chemotherapy alone, patients with Ph+ ALL have a uniformly poor prognosis with few survivors at five years after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/4-11\">",
"     4-11",
"    </a>",
"    ]. Allogeneic hematopoietic cell transplantation (allo-HCT) provides better results, curing approximately 30 to 60 percent of patients with Ph+ ALL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/7,12-18\">",
"     7,12-18",
"    </a>",
"    ]. The incorporation of a BCR-ABL1 tyrosine kinase inhibitor (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    ) into the treatment regimen has resulted in superior response rates, thereby allowing more patients to proceed to allo-HCT. It remains uncertain whether treatment only with the combination of chemotherapy plus a tyrosine kinase inhibitor will provide long-term survival results similar or better than all0-HCT in first remission. The treatment of Ph+ ALL is distinct from that of other types of ALL and is comprised of several stages that, in total, may span several years (",
"    <a class=\"graphic graphic_table graphicRef63462 \" href=\"mobipreview.htm?40/48/41740\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remission induction &mdash; Induction therapy aims to reduce the total body leukemia cell population from approximately 10",
"      <sup>",
"       12",
"      </sup>",
"      to below the cytologically detectable level of approximately 10",
"      <sup>",
"       9",
"      </sup>",
"      cells.",
"     </li>",
"     <li>",
"      Consolidation &mdash; Over 80 percent of adult patients with Ph+ ALL will attain a complete remission (CR) with induction chemotherapy that incorporates a tyrosine kinase inhibitor. However, without additional cytotoxic therapy, virtually all of these patients will relapse within a few weeks or months despite continuing on a tyrosine kinase inhibitor. In contrast, patients who receive post-remission therapy may expect five-year survival rates of 40 to 60 percent. Post-remission therapy includes an early allo-HCT or the continuation of chemotherapy plus tyrosine kinase inhibitor.",
"     </li>",
"     <li>",
"      Maintenance &mdash; Remission maintenance therapy is a standard component of the management of non-Ph+ ALL and is typically given for two to three years after consolidation chemotherapy. Maintenance chemotherapy is not used after allo-HCT for most patients with ALL; however, a tyrosine kinase inhibitor may be offered as maintenance after allo-HCT to some patients who had Ph+ ALL.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will discuss induction therapy for Ph+ ALL in adults. The following related subjects are presented separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical and pathologic features and diagnosis of ALL. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26007?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/20/30023?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Induction therapy for Ph chromosome negative ALL in adults. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23642?source=see_link\">",
"       \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Post-remission therapy for ALL in adults. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3497?source=see_link\">",
"       \"Post-remission therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/15/39161?source=see_link\">",
"       \"Post-remission therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of relapsed or refractory ALL in adults. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21753?source=see_link\">",
"       \"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of ALL in children. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31850?source=see_link\">",
"       \"Overview of the treatment of acute lymphoblastic leukemia in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58828833\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with ALL should undergo studies to evaluate for important disease characteristics as well as comorbidities. These are described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23642?source=see_link&amp;anchor=H2#H2\">",
"     \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\", section on 'Pretreatment evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of critical importance, studies must be performed rapidly to confirm the presence of BCR-ABL at presentation and rule out blastic transformation of chronic myeloid leukemia (CML). Morphologic examination of the bone marrow and peripheral blood by an expert hematopathologist will generally allow for the exclusion of blastic transformation of CML (ie, CML presenting in lymphoid blast phase, although there is no gold standard for discriminating these disorders). Bone marrow aspirate or peripheral blood blasts can be evaluated with reverse transcriptase polymerase chain reaction (RT-PCR) analysis for BCR-ABL (p190 and p210 transcripts) in order to rapidly confirm the presence of the Philadelphia chromosome. When possible, the absolute number of p190 or p210 transcripts should be measured relative to a housekeeping gene using real time quantitative PCR (RQ-PCR). Unlike the case in newly diagnosed chronic phase CML, high resolution molecular studies have detected additional mutations in the ABL kinase domain at diagnosis of Ph+ ALL that are likely to be resistant to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    or both. The clinical significance of these mutations remains to be determined. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15880?source=see_link&amp;anchor=H5#H5\">",
"     \"Detection of minimal residual disease in acute lymphoblastic leukemia\", section on 'Polymerase chain reaction (PCR)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19609?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of chronic myeloid leukemia\", section on 'Pathologic features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7816?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in blast crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The speed with which intensive remission induction chemotherapy should begin varies with the individual patient's condition and treatment options. In general, it is far more important to stabilize a patient's condition and correct or control co-morbidities, such as infection, bleeding, hyperuricemia, dehydration, renal dysfunction, anemia, and thrombocytopenia, than it is to immediately start chemotherapy. Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    or corticosteroids, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , should be used for cytoreduction of an elevated peripheral blast cell count while these problems are addressed. This interval of several days also allows for complete genetic screening where the results will have an impact on the choice of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58828926\">",
"    <span class=\"h1\">",
"     INDUCTION THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58830710\">",
"    <span class=\"h2\">",
"     Overview of induction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction therapy is administered with the goal of achieving a complete remission. A key component of this therapy is the use of a BCR-ABL tyrosine kinase inhibitor (TKI), which is directed against the protein product of the Philadelphia chromosome (",
"    <a class=\"graphic graphic_table graphicRef63462 \" href=\"mobipreview.htm?40/48/41740\">",
"     table 1",
"    </a>",
"    ). However, the TKI must be combined with other therapy since remissions induced by TKI therapy alone are short-lived. The largest experience has been with imatinib combined with conventional ALL chemotherapy regimens. Ongoing studies are evaluating the use of other TKIs, both in combination with ALL induction chemotherapy and in combination with steroids.",
"   </p>",
"   <p>",
"    For patients with newly diagnosed Ph+ ALL, we recommend induction chemotherapy plus a BCR-ABL TKI rather than chemotherapy alone. The combination of a TKI (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    ) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    should be considered for patients who are not candidates for conventional ALL chemotherapy regimens, ideally in the context of a clinical trial.",
"   </p>",
"   <p>",
"    Of importance, all patients with ALL have a high risk of central nervous system (CNS) involvement and all current treatment regimens include CNS prophylaxis. The method of CNS prophylaxis used should be consistent with that included in the prospective studies investigating the particular treatment regimen chosen (eg, intrathecal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    plus cranial irradiation used in the CALGB ALL regimen). This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23642?source=see_link&amp;anchor=H9#H9\">",
"     \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\", section on 'CNS prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58829265\">",
"    <span class=\"h2\">",
"     TKI plus chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concurrent administration of a BCR-ABL tyrosine kinase inhibitor (TKI) plus cytotoxic chemotherapy produces a complete remission (CR) in 90 to 95 percent of patients with Ph+ ALL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/19-27\">",
"     19-27",
"    </a>",
"    ]. Virtually all patients will attain a hematologic response and most treatment failures are due to early mortality (approximately 5 percent). This combination has not been compared with cytotoxic chemotherapy alone in a randomized trial. Instead, outcomes in patients receiving TKIs have been compared with historical controls. Patients with Ph+ ALL have a median survival time of less than nine months when treated with conventional ALL regimens alone due to a high early relapse rate. The addition of a TKI has resulted in significantly higher CR rates when compared with historical controls, with minimal additional toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/20-22,28-33\">",
"     20-22,28-33",
"    </a>",
"    ]. The CRs attained when a TKI is used appear to be more durable, thereby allowing more patients to proceed with post-remission therapy (eg, allogeneic hematopoietic cell transplantation). These higher CR rates and the feasibility of allogeneic transplantation have contributed to improved disease-free survival (DFS) and overall survival (OS).",
"   </p>",
"   <p>",
"    The following prospective studies are provided as examples that illustrate the outcomes seen in patients with Ph+ ALL treated with a TKI plus combination chemotherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase II trial of 92 patients with newly diagnosed Ph+ ALL evaluated the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      administered either concurrent with or alternating with combination chemotherapy for induction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/22\">",
"       22",
"      </a>",
"      ]. A CR was achieved in 95 percent. OS rates at two years were 43 and 36 percent for the concurrent and alternating schedule, respectively.",
"     </li>",
"     <li>",
"      A phase II trial of induction with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      plus combination chemotherapy in 80 patients with newly diagnosed Ph+ ALL resulted in a CR rate of 96 percent with approximately 70 percent achieving complete molecular remission (defined as no BCR-ABL by PCR) and one-year event-free and OS rates of 60 and 76 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/21\">",
"       21",
"      </a>",
"      ]. Interestingly, a significant number of patients who did not go on to receive an allogeneic transplant were still alive at one year. This compared favorably with historical controls treated at the same center with combination chemotherapy without imatinib who had a CR rate of 51 percent and significantly lower rates of one-year event-free and overall survival.",
"     </li>",
"     <li>",
"      A phase II trial of induction with combination chemotherapy plus short pulses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      in 59 patients with newly diagnosed Ph+ ALL reported a CR rate of 92 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/24\">",
"       24",
"      </a>",
"      ]. When compared with historical controls treated with chemotherapy without imatinib, patients who received imatinib had significantly higher rates of OS (38 versus 23 percent) and DFS (39 versus 25 percent) at five years.",
"     </li>",
"     <li>",
"      A phase II trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      plus combination chemotherapy in 45 patients with Ph+ ALL reported a CR rate of 96 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/23\">",
"       23",
"      </a>",
"      ]. Rates of OS and DFS at 18 months were 65 and 51 percent, respectively. This compared favorably with CR and 18-month OS and DFS rates of 71, 39, and 31 percent, respectively, in historical controls treated with chemotherapy without imatinib.",
"     </li>",
"     <li>",
"      A phase II trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      plus combination chemotherapy in 35 patients with Ph+ ALL reported a CR rate of 94 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/25\">",
"       25",
"      </a>",
"      ]. At a median follow-up of 14 months, the estimated two-year survival was 64 percent. Median DFS and OS had not been reached.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together with other nonrandomized trials, these studies strongly support the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy plus combination chemotherapy for the initial treatment of Ph+ ALL. Other nonrandomized trials have reported high CR rates with the use of the second generation TKI",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    in combination with chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/25,34\">",
"     25,34",
"    </a>",
"    ]. Imatinib and dasatinib have not been directly compared in this setting. (See",
"    <a class=\"local\" href=\"#H58829694\">",
"     'Choice of TKI'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58829685\">",
"    <span class=\"h3\">",
"     Choice of chemotherapy regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;While it is clear that the addition of a tyrosine kinase inhibitor (TKI) to induction therapy improves outcomes in patients with Ph+ ALL, the ideal chemotherapy regimen to use with a TKI is not known. Multiple induction regimens have been developed for ALL, most often based upon pediatric regimens. None have been directly compared in a prospective randomized trial. As such, there is no single best regimen for induction therapy in ALL, and patients should be encouraged to participate in clinical trials whenever possible.",
"   </p>",
"   <p>",
"    The following are examples of the most commonly used regimens for ALL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cancer and Leukemia Group B (CALGB study 8811 or 9111) ALL regimen uses a five-drug combination modified from regimens used for high-risk pediatric ALL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/6,35\">",
"       6,35",
"      </a>",
"      ]. Treatment is given in five courses that span 24 months. For patients with Ph+ ALL,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      is started during course 1 and continued indefinitely, depending upon toxicities. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23642?source=see_link&amp;anchor=H10#H10\">",
"       \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\", section on 'CALGB ALL regimen'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperfractionated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (Hyper-CVAD) alternating with high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      has also been used in adults with ALL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/25,36-40\">",
"       25,36-40",
"      </a>",
"      ]. This regimen includes a risk-stratified schedule of central nervous system prophylaxis with intrathecal methotrexate and intrathecal cytarabine. The dose-intensive phase spans six to seven months and is followed by 24 to 30 months of maintenance therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23642?source=see_link&amp;anchor=H12#H12\">",
"       \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\", section on 'Hyper CVAD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      French GRAALL-2003 regimen is another pediatric-inspired therapy that includes remission induction with high doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and asparaginase in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and intrathecal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23642?source=see_link&amp;anchor=H13#H13\">",
"       \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\", section on 'GRAALL 2003 regimen'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Details on these specific regimens are provided separately. All regimens include some form of central nervous system (CNS) prophylaxis. Preliminary reports suggest that the combination of lower intensity chemotherapy plus a TKI may result in acceptable complete remission rates with less toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/34\">",
"     34",
"    </a>",
"    ]. Given the lack of randomized trials, it is not possible to recommend one ALL induction regimen over another. A choice among these regimens must take into consideration the physician&rsquo;s comfort with administering the regimen, the side effect profile, and patient comorbidities. Whenever possible, a preference should be given for a regimen that has published outcomes when administered together with a TKI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58829694\">",
"    <span class=\"h3\">",
"     Choice of TKI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    have demonstrated activity in the treatment of Ph+ ALL. However, the ideal tyrosine kinase inhibitor (TKI) to administer with combination chemotherapy and the best schedule and duration of TKI treatment are not known. Of importance, neither TKI is effective in patients with a T315I mutation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       Imatinib",
"      </a>",
"      was the first TKI to be evaluated in combination with chemotherapy for Ph+ ALL and therefore has the most clinical experience and longest follow-up. In combination with chemotherapy, imatinib results in complete remission rates of 90 to 95 percent. Common side effects include myelosuppression, gastrointestinal complaints, fatigue, rash, fluid retention, and edema. Bullous skin lesions, liver toxicity, and heart failure are rare. (See",
"      <a class=\"local\" href=\"#H58829265\">",
"       'TKI plus chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27290?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\", section on 'Management of side effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"       Dasatinib",
"      </a>",
"      is a more potent TKI and has demonstrated activity in Ph+ ALL resistant to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      and in previously untreated Ph+ ALL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/25,42,43\">",
"       25,42,43",
"      </a>",
"      ]. It has activity against BCR-ABL kinase domain mutations that are resistant to imatinib, mutations that may be present at low levels at the time of Ph+ ALL diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/44\">",
"       44",
"      </a>",
"      ]. In combination with chemotherapy, dasatinib results in complete remission rates of approximately 95 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/25\">",
"       25",
"      </a>",
"      ]. Common side effects include myelosuppression, platelet dysfunction, and pleural and pericardial effusions. QT prolongation has been noted by ECG. Of particular interest in patients with ALL, dasatinib penetrates the blood-brain barrier, whereas imatinib does not. Dasatinib is approved by the US FDA and in Europe by the EMEA for use in the treatment of adults with Ph+ ALL with resistance or intolerance to prior therapy, including imatinib. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21753?source=see_link&amp;anchor=H14#H14\">",
"       \"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults\", section on 'Dasatinib'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27290?source=see_link\">",
"       \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is difficult at this time to recommend one TKI over another for individual patients.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    have not been compared directly in this setting. For most patients with newly diagnosed Ph+ ALL, we suggest the use of dasatinib, because of its greater potency, plus combination chemotherapy for induction therapy. Dasatinib is also the best choice for patients with resistance to or intolerance of imatinib.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58829273\">",
"    <span class=\"h2\">",
"     TKI plus steroid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of a tyrosine kinase inhibitor (TKI) with or without a corticosteroid is capable of producing complete remissions in previously untreated Ph+ ALL with low toxicity. This combination has not been directly compared with a TKI plus chemotherapy. For most patients with newly diagnosed Ph+ ALL, we prefer a TKI plus chemotherapy principally because of the greater experience and longer follow-up of patients treated with this combination. It also seems likely that chemotherapy would have a greater cytotoxic effect than steroids against ALL cells that were partially resistant to the TKI. If initial data are supported by subsequent studies, the combination of a TKI plus steroid may become an excellent option for patients, such as older adults, who are not able to tolerate combination chemotherapy.",
"   </p>",
"   <p>",
"    Relatively small prospective trials have been published regarding this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase II trial of 30 older adults (&gt;60 years old) with newly diagnosed Ph+ ALL evaluated the use of an outpatient induction regimen that consisted of a seven day &ldquo;pre-treatment&rdquo; with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (at escalating doses from 10 to 40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day) followed by combination therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      (800 mg daily) plus prednisone (40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily) for 45 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/31\">",
"       31",
"      </a>",
"      ]. No further chemotherapy was administered. The treatment was well tolerated. All evaluable patients attained a hematologic remission and one patient attained a complete molecular remission (defined as no BCR-ABL detectable by RQ-PCR); however, relapses were common. Median survival from diagnosis was 20 months.",
"     </li>",
"     <li>",
"      In a phase III trial of 55 older adults (&gt;55 years old) with newly diagnosed Ph+ ALL, induction therapy was randomly assigned with single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      or combination chemotherapy without imatinib [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/28\">",
"       28",
"      </a>",
"      ]. All patients received imatinib concurrently with all consolidation and reinduction therapy. The use of imatinib during induction was associated with significantly higher rates of complete remission (96 versus 50 percent) and lower rates of severe adverse events (39 versus 90 percent), but similar estimated overall survival at two years (42 percent for the entire cohort).",
"     </li>",
"     <li>",
"      Another phase II trial of 53 adults (&gt;18 years) with newly diagnosed Ph+ ALL administered an induction regimen that consisted of a seven-day &ldquo;pre-treatment&rdquo; with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (at escalating doses from 10 to 60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily) followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      (70 mg twice daily) for 84 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/45\">",
"       45",
"      </a>",
"      ]. Prednisone (60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily, with total dose capped at 120 mg daily) was administered for the first 24 days of dasatinib therapy and then tapered off by day 32. Intrathecal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      was administered for central nervous system prophylaxis. Post-induction therapy was at the discretion of the treating physician. All evaluable patients attained a hematologic remission, the majority by day 22. The rates of overall and disease-free survival at 20 months were 69 and 51 percent, respectively. At a median follow-up of 25 months, the projected median overall survival was 31 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these studies suggest that the combination of a TKI plus steroids is well tolerated and produces a high rate of hematologic complete remission. Importantly, this combination avoids the treatment related morbidity and mortality associated with combination chemotherapy. However, as with combination chemotherapy, induction with a TKI plus steroids is likely to be followed by relapse unless further consolidation therapy is administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83276421\">",
"    <span class=\"h1\">",
"     SPECIAL SCENARIOS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83276435\">",
"    <span class=\"h2\">",
"     Central nervous system involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of central nervous system (CNS) involvement for ALL is difficult to ascertain because all current treatment regimens include CNS prophylaxis. Nevertheless, ALL blasts are sometimes found in the CSF at diagnosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    at relapse. CNS leukemia is defined by the presence of leukemic blasts in a centrifuged preparation of cerebrospinal fluid (CSF) that does not have evidence of blood contamination. While the ideal treatment of patients with CNS involvement at the time of diagnosis is unknown, these patients are thought to be at higher risk for relapse. Cranial irradiation plus intrathecal chemotherapy is the mainstay of treatment of CNS involvement. Typically, 2400 cGy of radiation is given to the entire cranium, including the base of the brain, the back of the orbits, and the cervical spine to at least C2, over 12 doses. In addition, at least six doses of intrathecal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    should be administered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=see_link\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83277122\">",
"    <span class=\"h2\">",
"     Older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians often have concerns over the ability of older adults (eg, over age 60 years) to tolerate intensive chemotherapy. The management of Ph+ ALL in older adults can be complicated by an increased number of comorbidities. A comprehensive geriatric assessment may be useful in assessing comorbidity and functional status in the elderly patient, thus permitting the formulation of an appropriate, individualized treatment plan. Special considerations for the use of chemotherapy in the elderly population are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=see_link\">",
"     \"Systemic chemotherapy for cancer in elderly persons\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Older adults with Ph+ ALL and a good functional status should be considered for induction with a TKI plus chemotherapy such as that used for younger adults. When induction chemotherapy is not an option due to a poor functional status, the combination of a TKI plus steroid therapy may be administered for induction therapy. (See",
"    <a class=\"local\" href=\"#H58829273\">",
"     'TKI plus steroid therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83276456\">",
"    <span class=\"h2\">",
"     Young adults/adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients diagnosed with ALL between the ages of 16 and 21 are a special group in that they may be treated by either adult or pediatric hematologists. Several retrospective comparative analyses have reported that young",
"    <span class=\"nowrap\">",
"     adults/adolescents",
"    </span>",
"    with ALL treated on pediatric protocols demonstrate superior event-free and overall survival rates when compared with similar patients enrolled on adult ALL protocols. Accordingly, a number of prospective trials are evaluating the outcomes of young adults when treated by adult hematologists using pediatric regimens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23642?source=see_link&amp;anchor=H23#H23\">",
"     \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\", section on 'Young adults/adolescents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83276463\">",
"    <span class=\"h2\">",
"     Patients with Down syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Down syndrome who develop ALL have more treatment-related complications, including an increased frequency and severity of infections and mucositis, a higher incidence of hyperglycemia after treatment with corticosteroids, and an increased risk of developing cardiotoxicity after treatment with anthracyclines. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40649?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the outcome of acute lymphoblastic leukemia in children\", section on 'Down syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23642?source=see_link&amp;anchor=H23301004#H23301004\">",
"     \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\", section on 'Patients with Down syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83277691\">",
"    <span class=\"h2\">",
"     Patients with cardiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a history of congestive failure or other cardiac disease mandates careful monitoring of the large amounts of intravenous fluids used during induction remission and may influence the decision to use cardiotoxic drugs (eg, anthracyclines). A study of cardiac function (eg, ejection fraction measured by echocardiogram or MUGA) should be performed at baseline, especially for patients with a cardiac history, prior anthracycline exposure, or cardiovascular symptoms.",
"   </p>",
"   <p>",
"    Although anthracycline-based therapy is recommended for remission induction in patients with ALL, patients with underlying cardiac disease may not be able to tolerate the use of an anthracycline since this agent is toxic to cardiac cells.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     Doxorubicin",
"    </a>",
"    or other anthracyclines should not be administered to patients with a baseline ejection fraction below 30 percent. Patients with an ejection fraction greater than 30 percent may require monitoring. Contrary to common belief,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    is not a safe alternative in patients with cardiac disease. The use of anthracyclines in patients with cardiac disease is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link&amp;anchor=H15#H15\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Approaches for reducing the risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link&amp;anchor=H25#H25\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Pretreatment assessment and subsequent monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When an anthracycline is not an option, the combination of a TKI plus steroid therapy may be administered for induction therapy. (See",
"    <a class=\"local\" href=\"#H58829273\">",
"     'TKI plus steroid therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83277352\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;ALL is occasionally diagnosed during pregnancy. If detected during the first trimester, immediate termination of pregnancy followed by treatment of the leukemia is advisable, as combination chemotherapy given during this time is associated with an unacceptably high incidence of fetal abnormalities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetal loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of patients diagnosed later in pregnancy, such as late in the second trimester or during the third trimester, poses a difficult therapeutic dilemma. In the latter group of patients, if the leukemia is relatively indolent, it is sometimes possible to manage patients conservatively with leukapheresis, corticosteroids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transfusion, with induction of labor and delivery of a viable fetus as soon as possible. However, it is often difficult if not impossible to predict whether the ALL will take an indolent course for some weeks. The hazard of a delay of adequate ALL treatment until delivery should be carefully considered as it may imply a significant risk to the mother.",
"   </p>",
"   <p>",
"    There have been many reports of patients treated with chemotherapy later in their pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/46-50\">",
"     46-50",
"    </a>",
"    ]. The majority of these women have not aborted. There have been no reports of leukemia occurring in the children, nor an increased incidence of fetal abnormalities in infants who have been exposed to full-dose antileukemia chemotherapy during the later stages of gestation. A literature review of 160 pregnant patients treated with anthracyclines for a variety of malignancies, reported the delivery of normal infants in 73 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/46\">",
"     46",
"    </a>",
"    ]. Common unfavorable fetal outcomes included fetal death (9 percent), prematurity (6 percent), and malformations (3 percent).",
"   </p>",
"   <p>",
"    Tyrosine kinase inhibitors (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    ) are categorized as a pregnancy risk factor category D, indicating that there is evidence of human fetal risk, but that the benefits from use in pregnant women may be acceptable despite the risk. Experience with the use of these drugs during pregnancy largely comes from single agent TKI use in patients with chronic myeloid leukemia. In the absence of sufficient information concerning risks and benefits, personal preferences of the involved couple, along with input from a hematologist as well as an obstetrician expert in the detection of fetal abnormalities, will weigh heavily in the final decision. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27290?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83277204\">",
"    <span class=\"h1\">",
"     MONITORING DURING TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care is a critical component to the treatment of patients with acute leukemia. This includes the management of cytopenias, infections, tumor lysis, and other complications that accompany the treatment of acute leukemia. These are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=see_link&amp;anchor=H14#H14\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Supportive care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Combination chemotherapy for ALL is highly toxic, primarily to the hematopoietic system. Most patients will require hospitalization with blood product support during remission induction, but select patients may be treated as outpatients. Daily laboratory testing should be performed and generally includes a complete blood count and chemistries with renal function, glucose, and electrolytes. Calcium, phosphorus, and uric acid levels should be monitored until normal. Liver function tests should be assessed at least weekly.",
"   </p>",
"   <p>",
"    If there is unexpectedly severe or prolonged myelosuppression in patients taking 6-mercaptopurine or 6-thioguanine, the medication should be stopped and a genetic analysis obtained for determining thiopurine methyltransferase activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of pharmacogenomics\", section on 'Thiopurine methyltransferase'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83277211\">",
"    <span class=\"h1\">",
"     EVALUATING RESPONSE TO INDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial response to induction therapy is typically evaluated with a unilateral bone marrow aspirate and biopsy once adequate values for absolute neutrophil count",
"    <span class=\"nowrap\">",
"     (&gt;1000/microL)",
"    </span>",
"    and platelet count",
"    <span class=\"nowrap\">",
"     (&gt;100,000/microL)",
"    </span>",
"    are obtained. A core biopsy is required to assess marrow cellularity accurately.",
"   </p>",
"   <p>",
"    The primary goal of ALL induction therapy is achievement of an initial complete remission (CR), defined as the eradication of all detectable leukemia cells (less than 5 percent blasts) from the bone marrow and blood and the restoration of normal hematopoiesis (&gt;25 percent cellularity and normal peripheral blood counts). The importance of achieving a CR was shown in the International ALL trial; when all patients with ALL were analyzed (those with or without Ph chromosome), patients achieving or not achieving CR had overall survival rates of 45 versus 5 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/28/44489/abstract/51\">",
"     51",
"    </a>",
"    ]. Subsequent therapy is based upon the achievement of a CR:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once a CR is achieved, therapy must continue for an extended period of time to eliminate subclinical disease (minimal residual disease) known to contribute to relapse. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3497?source=see_link&amp;anchor=H4420436#H4420436\">",
"       \"Post-remission therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults\", section on 'Post-remission therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who do not achieve a CR with initial induction therapy are considered to have resistant disease. Early allogeneic transplantation can rescue some of these patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21753?source=see_link\">",
"       \"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While CR has historically been defined based upon morphologic criteria, it has been proposed that an assessment of minimal residual disease using immunological or molecular techniques can better define prognosis. As yet, prospective studies have not demonstrated that altering therapy based upon evidence of minimal residual disease after induction leads to a better outcome. The optimal time point to measure minimal residual ALL in adults (ie, immediately after achieving CR or later during post-remission therapy) for clinical decision-making is uncertain. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15880?source=see_link\">",
"     \"Detection of minimal residual disease in acute lymphoblastic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31625?source=see_link\">",
"     \"Clinical use of minimal residual disease detection in acute lymphoblastic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83277752\">",
"    <span class=\"h1\">",
"     POST-REMISSION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attainment of a CR is the first step in the treatment of ALL. However, relapse can be expected in the following weeks to months if no further therapy is given. Post-induction therapy is an essential component of the treatment of ALL. This is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3497?source=see_link\">",
"     \"Post-remission therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83276477\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/34/17955?source=see_link\">",
"       \"Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60604746\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) is a biologically and clinically distinct variant of ALL classified as ALL with t(9;22)(q34;q11.2);BCR-ABL1 in the WHO classification system. Treatment is markedly different than for other forms of ALL.",
"     </li>",
"     <li>",
"      All patients with ALL should immediately undergo studies to evaluate for the presence of BCR-ABL and to rule out blastic transformation of chronic myeloid leukemia as well as studies to evaluate for disease extent and comorbidities. (See",
"      <a class=\"local\" href=\"#H58828833\">",
"       'Pretreatment evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the diagnosis of Ph+ ALL is established, tyrosine kinase inhibitor (TKI)-based induction therapy is given with the goal of rapidly clearing the marrow of ALL blasts, restoring bone marrow function and attaining a complete remission (",
"      <a class=\"graphic graphic_table graphicRef63462 \" href=\"mobipreview.htm?40/48/41740\">",
"       table 1",
"      </a>",
"      ). For patients with newly diagnosed Ph+ ALL, we recommend induction chemotherapy plus a tyrosine kinase inhibitor (eg, imatinib or dasatinib) rather than chemotherapy alone (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The combination of a TKI plus steroids may be considered for patients who are not candidates for conventional ALL chemotherapy regimens, ideally in the context of a clinical trial. (See",
"      <a class=\"local\" href=\"#H58829265\">",
"       'TKI plus chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H58829273\">",
"       'TKI plus steroid therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ideal chemotherapy regimen to use with a TKI is not known. A choice among available regimens must take into consideration the physician&rsquo;s comfort with administering the regimen, the side effect profile, and patient comorbidities. Whenever possible, a preference should be given for a regimen that has published outcomes when administered with a TKI. (See",
"      <a class=\"local\" href=\"#H58829685\">",
"       'Choice of chemotherapy regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      have demonstrated activity in the treatment of Ph+ ALL, but the ideal TKI to administer with combination chemotherapy is not known. For most patients with newly diagnosed Ph+ ALL, we suggest the use of dasatinib plus combination chemotherapy for induction therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The general treatment principles apply to most disease presentations and patient populations. However, certain age groups and comorbidities have unique therapeutic implications. (See",
"      <a class=\"local\" href=\"#H83276421\">",
"       'Special scenarios'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chemotherapy for Ph+ ALL is highly toxic, primarily to the hematopoietic system, but also to the heart and nervous system. Most patients will require hospitalization with daily laboratory monitoring and supportive care with blood products and antibiotics. (See",
"      <a class=\"local\" href=\"#H83277204\">",
"       'Monitoring during treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Attainment of a complete remission is the first step in the treatment of Ph+ ALL. However, relapse can be expected in the following weeks to months if no further therapy is given. Post-induction therapy is an essential component of the treatment of Ph+ ALL. This is presented separately. (See",
"      <a class=\"local\" href=\"#H83277211\">",
"       'Evaluating response to induction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3497?source=see_link\">",
"       \"Post-remission therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/2\">",
"      Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007; 109:3189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/3\">",
"      Jones LK, Saha V. Philadelphia positive acute lymphoblastic leukaemia of childhood. Br J Haematol 2005; 130:489.",
"     </a>",
"    </li>",
"    <li>",
"     Larson RA, Dodge RK, Bloomfield CD, Schiffer CA. Treatment of biologically determined subsets of acute lymphoblastic leukemia in adults: Cancer and Leukemia Group B studies. In: Acute Leukemias VI: Prognostic factors and treatment strategies, Buchner T, Hiddeman W, Wormann B, et al. (Eds), Springer-Verlag, Berlin 1997. p.677.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/5\">",
"      Linker CA, Levitt LJ, O'Donnell M, et al. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood 1991; 78:2814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/6\">",
"      Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995; 85:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/7\">",
"      Gaynor J, Chapman D, Little C, et al. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. J Clin Oncol 1988; 6:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/8\">",
"      Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. Blood 2002; 100:2357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/9\">",
"      Gleissner B, G&ouml;kbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002; 99:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/10\">",
"      Faderl S, Kantarjian HM, Thomas DA, et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 2000; 36:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/11\">",
"      Preti HA, O'Brien S, Giralt S, et al. Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients. Am J Med 1994; 97:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/12\">",
"      Forman SJ, Schmidt GM, Nademanee AP, et al. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. J Clin Oncol 1991; 9:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/13\">",
"      Barrett AJ, Horowitz MM, Ash RC, et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1992; 79:3067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/14\">",
"      Chao NJ, Blume KG, Forman SJ, Snyder DS. Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1995; 85:3353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/15\">",
"      Miyamura K, Tanimoto M, Morishima Y, et al. Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation. Blood 1992; 79:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/16\">",
"      Stockschl&auml;der M, Hegewisch-Becker S, Kr&uuml;ger W, et al. Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 1995; 16:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/17\">",
"      Dunlop LC, Powles R, Singhal S, et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 1996; 17:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/18\">",
"      Snyder DS, Nademanee AP, O'Donnell MR, et al. Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia 1999; 13:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/19\">",
"      Lee S, Kim YJ, Min CK, et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005; 105:3449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/20\">",
"      Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004; 103:4396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/21\">",
"      Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006; 24:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/22\">",
"      Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006; 108:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/23\">",
"      de Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007; 109:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/24\">",
"      Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol 2010; 28:3644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/25\">",
"      Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 2010; 116:2070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/26\">",
"      Ribera JM, Oriol A, Gonz&aacute;lez M, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica 2010; 95:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/27\">",
"      Lee KH, Lee JH, Choi SJ, et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2005; 19:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/28\">",
"      Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer 2007; 109:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/29\">",
"      Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/30\">",
"      Pfeifer H, Wassmann B, Hofmann WK, et al. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res 2003; 9:4674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/31\">",
"      Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood 2007; 109:3676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/32\">",
"      Delannoy A, Delabesse E, Lh&eacute;ritier V, et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 2006; 20:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/33\">",
"      Gruber F, Mustjoki S, Porkka K. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol 2009; 145:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/34\">",
"      Rousselot P, Cayuela JM, Hayette S, et al. Dasatinib and low intensity chemotherapy for first-line treatment in elderly patients with de novo Philadelphia positive ALL (EWALL-PH-01): Kinetic of response, resistance and prognostic significance (abstract 172). Blood 2010; 116:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/35\">",
"      Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998; 92:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/36\">",
"      Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/37\">",
"      Weiser MA, O'Brien S, Thomas DA, et al. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen. Cancer 2002; 94:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/38\">",
"      Weiser MA, Cabanillas ME, Konopleva M, et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer 2004; 100:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/39\">",
"      Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004; 101:2788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/40\">",
"      Garg R, Kantarjian H, Thomas D, et al. Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy. Cancer 2009; 115:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/41\">",
"      Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009; 27:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/42\">",
"      Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007; 110:2309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/43\">",
"      Lilly MB, Ottmann OG, Shah NP, et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol 2010; 85:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/44\">",
"      Soverini S, Vitale A, Poerio A, et al. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica 2011; 96:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/45\">",
"      Fo&agrave; R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011; 118:6521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/46\">",
"      Germann N, Goffinet F, Goldwasser F. Anthracyclines during pregnancy: embryo-fetal outcome in 160 patients. Ann Oncol 2004; 15:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/47\">",
"      Chelghoum Y, Vey N, Raffoux E, et al. Acute leukemia during pregnancy: a report on 37 patients and a review of the literature. Cancer 2005; 104:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/48\">",
"      Pizzuto J, Aviles A, Noriega L, et al. Treatment of acute leukemia during pregnancy: presentation of nine cases. Cancer Treat Rep 1980; 64:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/49\">",
"      Reynoso EE, Shepherd FA, Messner HA, et al. Acute leukemia during pregnancy: the Toronto Leukemia Study Group experience with long-term follow-up of children exposed in utero to chemotherapeutic agents. J Clin Oncol 1987; 5:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/50\">",
"      Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004; 5:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/28/44489/abstract/51\">",
"      Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005; 106:3760.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16661 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-D8E73D39BC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_28_44489=[""].join("\n");
var outline_f43_28_44489=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H60604746\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H60603478\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58828833\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58828926\">",
"      INDUCTION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58830710\">",
"      Overview of induction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58829265\">",
"      TKI plus chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58829685\">",
"      - Choice of chemotherapy regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58829694\">",
"      - Choice of TKI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58829273\">",
"      TKI plus steroid therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83276421\">",
"      SPECIAL SCENARIOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83276435\">",
"      Central nervous system involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83277122\">",
"      Older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83276456\">",
"      Young adults/adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83276463\">",
"      Patients with Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83277691\">",
"      Patients with cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83277352\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83277204\">",
"      MONITORING DURING TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83277211\">",
"      EVALUATING RESPONSE TO INDUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83277752\">",
"      POST-REMISSION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83276477\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H60604746\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/16661\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/16661|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/48/41740\" title=\"table 1\">",
"      Treatment of newly diagnosed Ph positive ALL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19609?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26007?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/20/30023?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31625?source=related_link\">",
"      Clinical use of minimal residual disease detection in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27290?source=related_link\">",
"      Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15880?source=related_link\">",
"      Detection of minimal residual disease in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23642?source=related_link\">",
"      Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=related_link\">",
"      Overview of pharmacogenomics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40649?source=related_link\">",
"      Overview of the outcome of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31850?source=related_link\">",
"      Overview of the treatment of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/34/17955?source=related_link\">",
"      Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/15/39161?source=related_link\">",
"      Post-remission therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3497?source=related_link\">",
"      Post-remission therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7816?source=related_link\">",
"      Treatment of chronic myeloid leukemia in blast crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=related_link\">",
"      Treatment of leptomeningeal metastases (carcinomatous meningitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21753?source=related_link\">",
"      Treatment of relapsed or refractory acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_28_44490="Advanced case 3";
var content_f43_28_44490=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1295px;\">",
"  <div class=\"figure\" style=\"width: 581px\">",
"   <div class=\"ttl\">",
"    Advanced case 3",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 561px; height: 408px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_28_44490=[""].join("\n");
var outline_f43_28_44490=null;
var title_f43_28_44491="Abstinence rates by length of counseling session";
var content_f43_28_44491=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Meta-analyses of randomized trials: Smoking abstinence rates based on duration of counseling",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Total amount of contact time",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of arms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Estimated odds ratio (95% CI)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Estimated abstinence rate (95% CI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No minutes",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        11.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-3 minutes",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        1.4 (1.1-1.8)",
"       </td>",
"       <td>",
"        14.4 (11.3-17.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4-30 minutes",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        1.9 (1.5-2.3)",
"       </td>",
"       <td>",
"        18.8 (15.6-22.0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        31-90 minutes",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        3.0 (2.3-3.8)",
"       </td>",
"       <td>",
"        26.5 (21.5-31.4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        91-300 minutes",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        3.2 (2.3-4.6)",
"       </td>",
"       <td>",
"        28.4 (21.3-35.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;300 minutes",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        2.8 (2.0-3.9)",
"       </td>",
"       <td>",
"        25.5 (19.2-31.7)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. U.S. Department of Health and Human Services, Public Health Service 2008. Available at:",
"     <a href=\"file://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf\" target=\"_blank\">",
"      file://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_28_44491=[""].join("\n");
var outline_f43_28_44491=null;
var title_f43_28_44492="Resources for families of children with fears";
var content_f43_28_44492=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Resources for families of children with fears",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Books",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        For parents:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Monsters Under the Bed and Other Childhood Fears: Helping Your Child Overcome Anxieties, Fears and Phobias by Stephen W. Garber, Phd, Robyn Freedman Spizman, and Marianne Daniels Garber (Villard Books, 1993).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        When Your Child Is Afraid by Robert Schachter (Simon and Schuster, 1988).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No More Monsters in the Closet: Teaching Your Children to Overcome Everyday Fears and Phobias by Jeffrey L. Brown, MD (Crown Pub 1995).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        For children:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Night Light: A Story for Children Afraid of the Dark by Jack Dutro and Kenneth Boyle (Magination Press, 1991).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The Blammo - Surprise! Book: A Story to Help Children Overcome Fears by Stephen R. Lankton and Nancy Wiley (Margination Press, 1989).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Scary Night Visitors: A Story for Children with Bedtime Fears by Irene Wineman Marcus, Paul Marcus, and Susan Jeschke (Margination Press, 1991).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fang by Barbara Shook Hazen (Aladdin, 1991).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Freddie's Fears by Hilary Robinson (Franklin Watts Ltd, 2001).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arthur Goes to Camp by Marc Brown (Econ-CladBooks, 1999).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Franklin and the Thunderstorm by Paulette Bourgeois and Brenda Clark (Econo-Clad Books, 1998).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thunder Doesn't Scare Me! by Lynea Bowdish and John Wallace (Children's Press).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Let's Go Swimming with Mr. Sillypants by M. K. Brown (Crown, 1986).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cannonball Chris by Jean Marzollo (Random House, 1987).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alexander and the Terrible, Horrible, No Good, Very Bad Day by Judith Viorst (Simon &amp; Schuster Children&rsquo;s Books, 1972).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        When Mama Comes Home Tonight by Eileen Spinelli (Simon &amp; Schuster, 1998).&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Owl Babies by Martin Waddel.&nbsp;(Candlewick Press, 1996).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Websites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keep Kids Healthy (a pediatrician's guide to your children's health and safety) - www.keepkidshealthy.com/parenting_tips/fears.html",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        National Network for Child Care - www.nncc.org/Parent/uc.fears.html",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Child Development Institute - www.childdevelopmentinfo.com/disorders/fears.htm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nemours Foundation KidsHealth for parents - www.kidshealth.org/parent/emotions/feelings/anxiety.html",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        American Academy of Pediatrics - file://www.aap.org/pubserv/fears.htm",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Augustyn, M. Fears. In: Developmental and Behavioral Pediatrics, 2nd ed, Parker, S, Zuckerman, B, Augustyn, M (Eds), Lippincott Williams and Wilkins, Philadelphia 2005. p.188.",
"     <br>",
"      Pediatric Advisor, McKesson Health Solutions LLC.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_28_44492=[""].join("\n");
var outline_f43_28_44492=null;
var title_f43_28_44493="Contents: Pediatric oral health";
var content_f43_28_44493=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?17/55/18302\">",
"       Pediatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric oral health",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric oral health",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Anatomy and development",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/42/39590\">",
"           Anatomy and development of the teeth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/27/440\">",
"           Developmental defects of the teeth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/55/19320\">",
"           Oral habits and orofacial development in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gingivitis and periodontitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/45/32471\">",
"           Overview of gingivitis and periodontitis in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/60/8137\">",
"           Systemic conditions associated with periodontal disease in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/53/20313\">",
"           Complications, diagnosis, and treatment of odontogenic infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/27/31160\">",
"           Herpetic gingivostomatitis in young children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/45/32471\">",
"           Overview of gingivitis and periodontitis in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/52/23366\">",
"           Oral and systemic health",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Preventive care",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/26/33192\">",
"           Preventive dental care and counseling for infants and young children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Soft tissue lesions",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/32/30216\">",
"           Soft tissue lesions of the oral cavity in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/46/32489\">",
"           Evaluation and management of dental injuries in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/46/26340\">",
"           Reduction of temporomandibular joint (TMJ) dislocation",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-749EC263A0-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f43_28_44493=[""].join("\n");
var outline_f43_28_44493=null;
var title_f43_28_44494="Glycine deficit serum Na";
var content_f43_28_44494=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Association between the maximal difference between preoperative and postoperative serum sodium (S-Na) and glycine deficit (volume of retained fluid) assessed by simple linear regression",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 586px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     R: Pearson correlation coefficient. Each symbol may represent more than one subject; NS: not significant.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Istre O, Skajaa K, Schjoensby AP, Forman A. Changes in serum electrolytes after transcervical resection of endometrium and submucous fibroids with use of glycine 1.5 percent for uterine irrigation. Obstet Gynecol 1992; 80:218. Copyright &copy; 1992 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_28_44494=[""].join("\n");
var outline_f43_28_44494=null;
var title_f43_28_44495="Tracheoplast tracheomalacia";
var content_f43_28_44495=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Tracheoplasty for tracheomalacia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 222px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT images of a patient with tracheomalacia. A) Before surgery; B) After surgical tracheoplasty. Postoperatively, the trachea has a normal shape and size.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_28_44495=[""].join("\n");
var outline_f43_28_44495=null;
